PF-06882961 
Protocol C3421014Final Protocol, 05 October 2020
PFIZER CONFIDENTIAL
Page 1
A PHASE 1, NON-RANDOMIZED, OPEN-LABEL, SINGLE-DOSE, PARALLEL
COHORT STUDY TO COMPARE THE PHARMACOKINETICS OF PF-06882961
IN ADULT PARTICIPANTS WITH VARYING DEGREES OF HEPATIC
IMPAIRMENT RELATIVE TO PARTICIPANTS WITHOUT HEPATIC
IMPAIRMENT
Study Intervention Number: PF-06882961
Study Intervention Name: [CONTACT_107107]:
EudraCT Number: Not Applicable
Protocol Number: C3421014
Phase: 1
Short Title: Pharmacokinetic Study of PF-06882961 in Participants With and 
Without Varying Degrees of Hepatic Impairment
This document and accompanying materials contain confidential information belonging to [COMPANY_007].  Except as 
otherwise agreed to in writing, by [CONTACT_22788], you agree to hold this information in confidence and not copy or disclose it to others (except where required by [CONTACT_1289]) or use it for unauthorized purposes.  In the event of any actual or suspected breach of this obligation, [COMPANY_007] must be 
promptly notified.CCI
PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZER CONFIDENT IAL
Page 2Protocol Amendment Summ ary of Cha nges Table
Document History
Document Version Date Summary and Rationale for Changes
Original Protocol 05October 2020 N/A

PF-[ADDRESS_118887] OF TABLES................................................................................................................. ....8
1. PROTOCOL  SUMMARY.....................................................................................................9
1.1. Synopsis .................................................................................................................. ..9
1.2. Schema .................................................................................................................... 11
1.3. Schedule of Activities .............................................................................................12
2. INTRODUCTION ...............................................................................................................1 4
2.1. Study R ationale .......................................................................................................14
2.2. Background .............................................................................................................14
2.2.1. Nonclinical Overview.................................................................................15
[IP_ADDRESS]. Nonclinical Pharmacology ........................................................15
[IP_ADDRESS]. Nonclinical Safety .....................................................................16
2.2.2. Clinical Overview.......................................................................................16
[IP_ADDRESS]. Clinical Safety...........................................................................[IP_ADDRESS]. Clinical Pharmacokinetics.........................................................17
2.3. Benefit/Risk Assessment.........................................................................................18
2.3.1. Risk Assessment .........................................................................................182.3.2. Benefit Assessment.....................................................................................202.3.3. Overall Benefit/Risk Conclusion................................................................20
3. OBJECTIVES AND ENDPOINTS .....................................................................................214. STUDY DESIGN................................................................................................................ .21
4.1. Overall Design.........................................................................................................214.2. Scientific Rationale for Study Design.....................................................................224.3. Justification for Dose ..............................................................................................244.4. End of Study Definition ..........................................................................................24
5. STUDY POPULATION ......................................................................................................24
5.1. Inclusion Criteria.....................................................................................................25
5.1.1. Participants in All Cohorts..........................................................................255.1.2. Additional Inclusion Criteria for Participants without Hepatic 
Impairment (Cohort 1 Only ) ............................................................................25CCI
PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZER CONFIDENT IAL
Page 45.1.3. Additional Inclusion Criteria for Participants with Impaired Hepatic 
Function (Cohorts 2, 3, and 4 Only ) ................................ ................................ 26
5.2. Exclusion Criteria ................................ ................................ ................................ ....27
5.2.1. Participants in All Cohorts..........................................................................27
5.2.2. Additional Exclusion Criteria for Participants without Hepatic
Impairment (Cohort 1 Only ) ............................................................................29
5.2.3. Additional Exclusion Criteria for Participants with I mpaired Hepatic 
Function (Cohorts 2, 3, and 4 
Only ) ................................................................30
5.2.4. Criteria for Dosing on Day  1 ......................................................................31
5.3. L ifesty le Considerations ..........................................................................................31
5.3.1. Meals and Dietary  Restrictions ...................................................................31
5.3.2. Caffeine, Alcohol, and Tobacco .................................................................32
5.3.3. Activity .......................................................................................................33
5.3.4. Contrace ption ..............................................................................................33
5.4. Screen Failures ........................................................................................................33
6. STUDY INTERVENTIO N
..................................................................................................33
6.1. Study  Intervention(s) Administered ........................................................................34
6.1.1. Administrat ion............................................................................................34
6.2. Preparation/Handling/Storage/Accountability ........................................................34
6.2.1. Preparation and Dispensing ........................................................................35
6.3. Measures to Minimize Bias: Randomization and Blinding .....................................35
6.3.1. Allocation to Study Intervention ................................................................35
6.4. Study  Intervention Compliance ...............................................................................36
6.5. Concomitant Therapy ..............................................................................................36
6.5.1. Participants without Hepatic Impairment (Cohort 1, Only )
.......................36
6.5.2. Participants with Impaired Hepatic Function (Cohorts 2, 3, and 4) ...........37
6.5.3. Rescue Medicine .........................................................................................37
6.6. Dose Modification ...................................................................................................37
6.7. I ntervention After t he End of the Study ..................................................................37
7. DI SCONTINUATION O F STUDY INTERVENTION AND PARTI CIPANT 
DISCONTINUATION/WI THDRAWAL ...........................................................................37
7.1. Discontinuation o f Study  Intervention ....................................................................37
7.2. Participant Discontinuation /Withdrawal From the Study .......................................[ADDRESS_118888] to Follow up
....................................................................................................38
8. STU DY ASSESSMENTS AND P ROCEDURES ...............................................................39
8.1. Efficacy  Asses sments ..............................................................................................40
8.2. Safet y Assessments .................................................................................................40
8.2.1. Phy sical Examinations ................................................................................40
8.2.2. Vital Signs ..................................................................................................40
[IP_ADDRESS]. Temperature ..............................................................................41
8.2.3. Electrocardiograms
.....................................................................................41
8.2.4. Clinical Safety  Laboratory  Assessments ....................................................42
8.2.5. COVID -
19 Specific Assessments...............................................................43
8.2.6. Glucose Monitoring ....................................................................................43
[IP_ADDRESS]. Definition and Severit y of H ypogl ycemic Adverse Event 
(HAE) ................................................................................................43
8.2.7. Pregnancy  Testing ......................................................................................44
8.3. Adverse Events and Serious Adverse Events
..........................................................45
8.3.1. Time Period and Frequency  for Collecting AE and SAE Information .......45
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety ...............................................46
[IP_ADDRESS].
Recording Nonserious AEs and SAEs on the CRF...................46
8.3.2. Method of De tecting AEs and SAEs ..........................................................46
8.3.3. Follow -up of AEs and SAEs .......................................................................46
8.3.4. Regulat ory Reporting Requirements for SAEs ...........................................46
8.3.5. Exposure During Pregnancy  or Breastfeeding, and Occupational 
Exposure ................................ ................................ ................................ .......... 47
[IP_ADDRESS]. Exposure During Pregnancy ......................................................47
[IP_ADDRESS]. Exposure Duri ng Breastfeeding ................................................48
[IP_ADDRESS]. Occupational Exposure .............................................................49
8.3.6. Cardiovascular and D eath Events ...............................................................49
8.3.7. Disease -Related Events and/or Disease -
Related Outcomes Not 
Qualifying as AEs or SAEs ..............................................................................[ADDRESS_118889] ................................ ............................. 49
[IP_ADDRESS]. Lack of Efficacy ........................................................................49

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZER CONFIDENT IAL
Page 68.3.9. Medical Device Deficiencies ......................................................................50
8.3.10. Medication Errors .....................................................................................50
8.4. Treatment of Overdose
............................................................................................50
8.5. Pharmacokinetics ....................................................................................................51
8.5.1. Plasma for Anal ysis of PF -
06882961.........................................................51
8.5.2. Plasma for Determination of PF
-06882961 Unbound Fraction 
Protein Binding ................................................................................................52
8.6. Pharmacod ynamics ..................................................................................................53
8.7.Genetics ...................................................................................................................53
8.7.1. Specified Genetics ......................................................................................53
8.7.2. Banked Biospecimens for Genetics ............................................................53
8.8. Biomarkers ..............................................................................................................53
8.9. I mmunogenicit y Assessments .................................................................................53
8.10. Health Economics .................................................................................................53
9. STATI STICAL CONSI DERATIONS
................................................................................53
9.1. Statistica l Hypotheses .............................................................................................54
9.2. Sample Size Determination .....................................................................................54
9.3. Analy sis Sets ...........................................................................................................54
9.4. Statistical Analy ses.................................................................................................55
9.4.1. Pharmacokinetic Analy ses..........................................................................55
[IP_ADDRESS]. Derivation of Pharmacokinetic Parameters ...............................55
[IP_ADDRESS]. Statistical Methods for Pharmacokinetic Data ..........................56
9.4.2. Safet y Anal yses..........................................................................................57
[IP_ADDRESS]. Electrocardiogram Analy ses......................................................58
9.4.3. Other Anal yse(s).........................................................................................58
9.5.Interim Anal yses.....................................................................................................58
9.6. Data Monitoring Committee or Other Independent Oversight Committee ............. 58
10. SUPPORTING DOCUM ENTATION AND OPERATI ONAL 
CONSI DERATIONS ..........................................................................................................59
10.1. Appendix 1: Regulatory , Ethical, and Study  Oversight Considerations ...............59
10.1.1. Regulatory and Ethical Considerations ................................ .................... 59

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZER CONFIDENT IAL
Page [IP_ADDRESS]. Reporting of Safety  Issues and Serious Breaches of the 
Protocol or I CH GCP ................................ ................................ ......... 59
10.1.2. Financial Disclosure .................................................................................60
10.1.3. Informed Consent Process
........................................................................60
10.1.4. Data Protection .........................................................................................61
10.1.5. Dissemination of Clinical Study  Data ......................................................61
10.1.6. Data Qualit y Assurance ............................................................................63
10.1.7. Source Documents ....................................................................................64
10.1.8. Study  and Si te Start and Closure
..............................................................64
10.1.9. Publicat ion Policy .....................................................................................65
10.1.10. Sponsor’s Qualified Medical Personnel .................................................66
10.2. Appendix 2: Clinical Laboratory  Tests .................................................................67
10.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting ......................................................................68
10.3.1. Definition of AE .......................................................................................68
10.3.2. Definition of SAE
.....................................................................................69
10.3.3. Re cording/Reporting and Follow
-up of AEs and/or SAEs .......................70
10.3.4. Reporting of SAEs
....................................................................................74
10.4. Appendix 4: Contraceptive Guidance ...................................................................75
10.4.1. Male Par ticipant Reproductive Inclusion Criteria ....................................75
10.4.2. Female Participant Reproductive Inclusion Criteria .................................75
10.4.3. Woman of Childbearing Potential ............................................................75
10.4.4. Contraception Methods .............................................................................76
10.5. Appendix 5: Genetics ............................................................................................78
10.6. Appendix 6: L iver Safety : Suggested Actions and Follow -up Assessments ........79
10.7. Appendix 7: ECG Findings o f Potential Clinical Concern
...................................81
10.8. Appendix 8: 
Child -Pugh Classification (CPC) of L iver Dy sfunction ...................83
10.9. Appendix 9: 
Prohibit ed Prior/Concomitant Medications ................................ ......[ADDRESS_118890] OF T ABLES
Table 1. Hepatic Function Categories Based on Child -Pugh Score ................................ ........ 21
Table 2. Expected Widths of the 90% CI s (with 80% Coverage Probability ) 
for Different Possible Estimated Effects ..................................................54
Table 3. Plasma PK Parameters ..............................................................................56
Table 4. Protocol -Required Safet y L
aboratory  Assessments .................................67
Table 5. Scoring for Child Pugh Classification22...................................................83
Table 6.
Derivation of Child Pugh Classification Score.........................................83
Table 7. Determination of Encephalopathy  Grade .................................................83

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZER CONFIDENT IAL
Page 91.PROTOCOL SUMMARY 
1.1. S ynopsis 
Short T itle: Pharm acokinetic Study of PF -[ADDRESS_118891] of 
varying degrees of hepatic 
impairmen t on the plasma pharmacokinetics (PK) of 
PF-06882961 following admi nistra tion of a single oral dose of PF -06882961 .
Objectives and Endpoints
Objectives Endpo ints
Prim ary: Prim ary: 
To compare the PK of PF -06882961 follow ing 
administration of a single or al dose in adult 
participants with varying degrees o f hepatic 
impairment re lative to age -and body 
weight -matched participants without hepatic 
impairm ent.Plasma: C max, AUC inf, AUC last,fuas data permit.
Seco ndary: Secondary: 
To evaluate the safety an d tolerabil ity of a 
single oral dose of PF -06882961 when 
administer ed to ad ult participants with varying 
degrees of hepatic impairment and in age -and 
body w eight -matched participants without 
hepatic impairment .Assessment of treatment emergent AEs, clinic al 
laborato ry abnormalities, vital signs, ECG 
parame ters.
Tertiary /Explo ratory: Tertiary/Exploratory: 
To compare additional PK parameters of 
PF-06882961 following administration of a 
single oral dose in adu lt participants with 
varying degrees of hepati c impairmen tand in 
age-and body weight -matched participants 
witho ut hepatic impairment .Plasma: C max,u, AUC inf,u, AUC last,u, CL/F, CL u/F, 
Vz/F, V z,u/F,Tmax, t1/2as data permit.
Overall Design
This is a non- randomized, open -label, single -dose, parallel -cohort, mul ticenter study  to 
investigate the effect of vary ing deg rees of hepatic function on the plasma PK of
PF-
06882961 after a single, oral 20mg d ose a dministered in the fed state.  Safety  and 
tolerabilit y will be evaluated throughout the study.

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZER CONFIDENT IAL
Page 10Numb er of Parti cipants
Approximately  24participants wil l be enrolled to study intervention such that approximately  
24evaluable participants complete the s tudy.
Note: "Enrolled" means a participant's agreement to participate in a clinical study  following 
compl etion of t he informed consent process. 
Interventi onGroups and D uratio
n
A total of approximately  24participants with varying degrees of hepatic func tion will be 
administered a single, oral 20mg dose of PF-06882961 in the fed state as shown in the tabl e 
below . 
Hepatic Function Categories Based on Child Pugh -Score
Cohort Description Child -Pugh Score Number of 
Participant s
1 Without hep atic impairment Not Applicable 6a
2 Mild hepatic impairment Class A (5 t o 6 points) 6
3 Moderate hepatic impairment Class B (7 t o9 points) 6
4 Severe hepatic impairmen t Class C (10 t o 15 p oints) 6b
a. Additional participants may be dosed to a maximum of 8 participants to en sure mean age 5years and mean body 
weight 10kg of this cohort is aligned with the pooled average assessed when ≥ 75% of participants are dosed 
acros s the other 3 cohorts .
b. If recruitment across the sites selected proves to be prohibi tive, study will dose only 4 participants in this cohort.   
Categorization of participants into Cohort 2-4, inclusive, will be done ba sed on Child -Pugh 
scores determined ,as described i n Appendix 8 , at the sc reening visit. Participants will be 
dosed in a staged manner such that those with moderate and severe hepatic impairment 
(Cohorts 3 and 4) wi ll be evaluated first followed by  [CONTACT_107071] (Coho rt 2).  Participants without hepatic impairment ( Cohort 1) will be recruited 
near the end of the stud y
to match the average demographics (at a minimum, age and weight; 
andgender as much as practicall y possibl e)across the pooled Co horts [ADDRESS_118892] be obtained before proceeding with recruitment for 
participants on Cohort 1 or Cohort 2.
For individual participants, the total durat ion of part icipation from the screening visit to the
follow -upvisit will range from approximate ly 5 weeks (minimum) to approximately  9weeks 
(maximum) .
Data Monitoring Committee or Other Independent Oversight Committee
A data monitoring committee or inde pendent ove rsight committee will not be utilized.

PF-[ADDRESS_118893] of vary ing degr ees of he patic impairment on PK parameters will be assessed b y
constructing 90% confidence intervals (CI) around the estimated difference between each of 
theTest (hepatic impaired) cohorts and the Reference (wit hout hepatic impairme nt) cohort.
A 1-way analysis of variance (ANOVA) will be used to compare the natural log transformed
PF-
[ADDRESS_118894], and fraction unbound (fu), as data permit, for each of 
thehepatic impairment cohorts (Test) to th e cohort withou t hepa ti
cimpairment (Refe rence). 
Estimates of the adjusted mean differences (Test - Reference), and corresponding 90% CIs , 
will be obtained from the model. These will be exponentiated to provide es timates of the 
ratio of adjusted geometri c means (Test/R eferen ce)and 90% CI sfor the ratios.
1.2. S chema

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZER CONFIDENT IAL
Page 121.3. S chedule of Activ ities
The SoA table provides an overview of the protocol visits and procedures.  Refer to the STUDY ASSESSMENTS AND 
PROCEDURES section of the prot ocol for detailed informat ion on each procedure and assessment required for compliance with the 
protocol. The investigator may  sche dule visits (
unplanned visits) in addition to those liste d in the SoA table, in order to conduct 
evaluations o r assessments r equire d to protect the we ll -being of the participant.
Visit Identifier/Day
[for list of abbreviations refer toSection 10.10 ]Screen ing
-28 to -2Day 
-1Day 1 Day 2 Day 3 ET Follow-upa
Day 30 ±[ADDRESS_118895] Dose -- 01234567810 12 14 24 36 48 -- --
Informed consent & demography x
Outpatient visit x x
Inpat ient stay at Clinical Rese arch Uni t x             x
Eligibilit yassessm ent x x
Medical history x x
Physical exam (height & body weight at screen ing,only)bx x x x
Brea th alcohol test& Urine drug tes t x x
Alcohol/t obacco & contraception use x x x x xc
(Update) prior/concomitant treatments x x x x
Single, supi[INVESTIGATOR_050]12-lead ECG x x x x
Single, seate dvital sign s(BP,pulse rate ,temperature ) x x x x x x
Serious and non -serious adverse event monitoring x x              x x x
Standard mealsdx x x x x x x x
Investigati onal product administration xe
Blood & Urinefor clinical lab oratory tests after 4-hour fast x x x x
Serology for FSH ( females o nly), HbA1c , HIV, HBsAg, 
HCVAb /RNAx
Serum pregnancy test (fema lesonly) x x x x
COV ID-[ADDRESS_118896] (WOCBP, only)hx x
a. Visit to be performed as telepho ne contact [INVESTIGATOR_1238] m ust occur [ADDRESS_118897], if deemed necessary by [CONTACT_093].
b. Complete physical exam (PE) at screen ing; at all o ther time p oints limited PE , at investigat ordiscretion (seeSection 8.2.1 ).

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZER CONFIDENT IAL
Page 13c. In confirma tion of appropriate contraception use only.
d. Meals/snacks to be served at clock times matching approximate ly 0H, 4 H, 7H, 10 H, and 14H (optional) relative to do sing on Day 1 (while in patient).
e. Dosing to occur with standard morning meal provi dedapproximately [ADDRESS_118898] be reviewed and de emed a cceptable (ie, negative) to continue par ticipation in the study.

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page 142.INTRODUCTI ON
Glucagon -like pep tide-1 (GL P-1) is a neuroendocrine hormone that is predominantly  
released from the small intestine in response to food intak e.1  GLP - 1 acti vation of the G LP-1 
receptor (GLP -1R) stimulates ins ulinrelease, inhibi ts glucagon secretion in a 
glucose -dependent manner, and delay s gastric empty ing.2,[ADDRESS_118899] approved for the treatment of type 2 diabetes 
mellitus (T2D M).
2.1.Study Rationale 
The primary purpose of thi s non- randomized, open -label s tudyis to char acterize the effect of 
varying degree s ofhepatic impa irmenton the plasma pharmacokinetics (PK) of 
PF-[ADDRESS_118900] more th an 424 million people 
worldwid
e,6andthe prevalence of T2DM w ithin the United S tates (US) is estimated to range 
from 12 to 14%.7  T2DM is characterized b y insulin re sistance, a disorder in which cells do 
not respond effectivel y to insulin, re s
ulting in higher blood glucose levels. Elevate d blood 
glucose levels and increas ing severity  of insulinresistance result in the need for more insulin 
over time, eventuall y resu lting in progressive pancreati c -cell failure.[ADDRESS_118901] an increased risk of devel opi[INVESTIGATOR_107057], including n ephropathy , neuropathy , retinopath y, 
cardiovasc ular disease and stroke; and ar e at2 to 4 times increased r iskof mortalit y than 
adults who do not hav e diabete s.9  While existing pharmacological options for the treatment 
of diabetes may  prov ide satisfactory  glycemic control for some pati
ents,there remains a large 
numb e r of patient s who do not achieve target gl ycated hemo globin (HbA1c ) levels, 
suggesting a need for additional therapeutic options.
Marketed injecta ble GLP -1R agonists have demon strated robust gl ycemic efficacy , weight 
loss, and c ardio vascular safet y, wit h some agent s demonstrating cardiovascular benefit.[ADDRESS_118902] is 
expected to improve glucose control and r educe HbA1c levels in patients with T2DM, whi le 
decreasing food intake and body  weightand avoiding the subcutaneous injection required by  
[CONTACT_107072] y available peptidic GL P-1R agon ists.

PF-06882961 
Protocol C3421014Final Protocol, 05 October 2020
PFIZER CONFIDENTIAL
Page 152.2.1. Nonclinical Overview
[IP_ADDRESS]. Nonclinical PharmacologyIn vitro primary pharmacodynamics (PD) studies demonstrated that, in cells expressing 
recombinant human and cynomolgus monkey GLP-1R, PF-06882961 dose-dependently promotes 3’-5’-cyclic adenosine monophosphate (cAMP) production.  In vivo, PF-[ADDRESS_118903] (IVGTT) in cynomolgus monkeys in a dose and concentration dependent manner.  PF-06882961 was also shown to reduce food intake in cynomolgus monkeys.  In all in vivo studies, efficacious plasma levels were consistent with the in vitro potency.  
Refer to the investigator’s brochure (IB) for more details on the nonclinical pharmacology of 
PF-06882961.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CCI
PF-06882961 
Protocol C3421014Final Protocol, 05 October 2020
PFIZER CONFIDENTIAL
Page 16 
 
.
[IP_ADDRESS]. Nonclinical Safety
General toxicology studies have been completed in cynomolgus monkeys up to 6 months in 
duration (with a 3-week lead-in and 1-month recovery) and in rats up to 6 months in duration (with a 1-month recovery).   
 
 
 
 
  
Embryo-fetal developmental studies were completed in rats and rabbits.   
 
 
 
 
 
 
PF-[ADDRESS_118904] completed dosing with 
PF-06882961.  
  In 
the multiple dose study C3421002, PF-06882961 doses up to 120 mg BID (or matching placebo) for 28 days were generally safe and well-tolerated in adult participants with T2DM on a background of metformin therapy, and safety results from this study are provided in CCI
CCI
CCI
CCI
CCI
CCI
PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page 17Section [IP_ADDRESS]. Refer t o the IB for mo re details o n these studies and the k nown drug class 
effectsof marketed injectable GL P-1R ag onists.
[IP_ADDRESS]. Clinical Safety
Clinical data fro m the completed C3421001, C3421002 and C3421003 studies are provid ed 
in the I B forPF-06882961.
In stud y C3 421002, PF -[ADDRESS_118905] bo ina 
3:1randomization ratio, and [ADDRESS_118906] eted the study . Six par ticipants 
discont inued from the study , of which 2 disconti nuations were due to treatment -related 
TEAEs, and 4 withdrew during the treatment or f ollow -up period for non- treatm ent related 
reasons.
A total of 319 all -causality treatmen t -emergent adverse even ts (TEAEs) were r eported in 
these participants, of which a majorit y (294 or 92%) were mild in intensity, 23 (or 7%) were 
moderate, and 2 (or 1%) were severe in inten sity.  
The total number of TEAEs gener ally increased with higher da ily doses of PF -06882961. 
The most freq
uentlyreported TEAEs (by [CONTACT_107073]) in these cohorts have been 
nausea (48), d yspepsia (32), vomiting (26), diarrhe a (24), headache (23), constipa tion(20), 
and decreased appe tite (19). In addition, ther e was 1 symptomatic hy pogly cemic adverse
e
vent (H AE) that was reported in 1 participant in the 120 mg BID group. This A E was 
non-fasting, mild in severity  and of limi ted duration. No deaths occur redin the C3421002 
study . Two participants experien ced 2 severe TEAEs during the study, 1 of whic h occurred 
in the dosing period and
was considered treatment related, the other occurred during the 
follow -up period and was no t considered treatment related .One participant experienced
2 non- treatmen t-related SAEs, 1 of which occurred i n thefollow -up per i od and the other 
occurred outside of the study  reporting period.
While there were isolated values for laboratory  tests, vita l signs and 
electrocardiogram 
(ECG)intervals outside of the reference rang es,no clear adverse trends were appa rentin 
these par ameters.  As has been reported for m arketed GL P-1R agonists,10,11increas es in heart 
rate have been obs erved, with mean increases ran ging from 5 to 15 beats per minute ( bpm)
across dose s administered to date,and most heart rate values wi thin the normal range.
[IP_ADDRESS]. Clinical Pharmacokine tics
The clinical pharmac okinetics (PK) of PF -[ADDRESS_118907] udies: C3 421001, C3421002, and C34210 03. The results of the se 
completed studies are summa rized in the PF -[ADDRESS_118908] for the 
BID IR formulation treatments, with mean ratios based on dose normalized AUC 24(Rac) 
values ranging from 1.203-2.009.  Day 28 plasma exposure as measured by [CONTACT_107074]
24values appeared to increase in an approximate dose proportional manner across all IR 
treatments.  Mean t ½values on Day 28 across all treatments ranged between 4.681 to 8.090 
hours, and no apparent trends were observed across various treatments, regimens, or doses administered.  Inter-participant variability for PF-06882961 exposure was based on geometric mean was 31%-87% for AUC
24and 32%-94% for C maxand on Day 28 across all 
treatments and cohorts.  
 
 
 
 
2.3. Benefit/Risk Assessment
More detailed information about the known and expected benefits and risks and reasonably 
expected adverse events of PF-06882961 may be f ound in the IB, which is the SRSD for this 
study. 
2.3.1. Risk Assessment
Potential Risk of Clinical 
SignificanceSummary of Data/Rationale for 
RiskMitigation Strategy
Study Intervention(s) PF-[ADDRESS_118909] labeling for injectable GLP-1R agonists (ie, liraglutide, dulaglutide, and exenatide) due to dose-dependent and treatment 
duration-dependent thyroid 
C-cell tumors in nonclinical studies in rats and mice at clinically relevant exposures. 
Thyroid C-cell tumors have not 
been observed with PF-06882961 
in clinical or nonclinical studies. Participants with a personal or 
family history of medullary thyroid carcinoma or MEN2 are excluded from the clinical development program. CCI
CCI
PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page 19Potential Ris k of Clinical 
SignificanceSummary of Data/Rati onale for 
RiskMitigation Stra tegy
Study Intervention(s) PF-[ADDRESS_118910] l abeling for injectable 
GLP -1R agonists (ie, liraglutide , 
exenatide and dulaglutide). 
Pancreatitis has not been 
observed in the PF -[ADDRESS_118911] an 
increased risk of h ypoglycemia 
(such as insul in or 
sulfonylureas), an increased risk 
for hypoglycem ia was observed. 
Only 1 adverse event of mild 
hypoglycaemia has been reported
in the clinical development 
program to date.Blood glucose is monitored 
frequent ly during clinica l studies,
and participants are monitored for 
signs or symptoms o f 
hypoglycemia. The single dose and 
dose l evel administered i n this study 
minimize any poten tialrisk.
Impairm ent in ren alfunction In rats, minimal renal tubular 
vacuolati on w as observed, but
this finding was considered to be 
non-adverse.
In the clinical trial program only 
1mild adverse even t (PT Blood 
creatinine increased) has been 
observed in the clinical trial 
program .Study ex clusio n criteria include 
participant s with significant renal
impairment.
Gastrointestinal adverse reactions The potential risks are based o n 
product labeling for injectable 
GLP -1R agonis ts (ie, liraglutide, 
exenatide and dulaglutide).
In addition , gastrointesti nal
adverse events, the majority of 
which were mild in s
everity, 
have been observed in the 
clinical program with 
PF-06882961. In nonc linical 
studies wit h PF-06882961, 
gastrointesti nal adverse effects 
have been seen in rats and 
monkey s.Participants are mo nitored during 
the clinical studies t o prevent 
potenti alsequelae of any severe 
gastrointestinal reactions, 
eg,dehydration. Exclusio n criteria 
include any factor that may affect 
drug absorption, such as bariat ric
surgery, ac tive inflammato rybowel 
diseas e or any intestinal resection. 

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page 20Potential Ris k of Clinical 
SignificanceSummary of Data/Rati onale for 
RiskMitigation Stra tegy
Study Intervention(s) PF-[ADDRESS_118912] of vary ing degrees of hepatic impairment on the 
PK of PF -
06882961.  Results from this study  will be used in conjunction with c ollective 
safety, efficacy , and PK/P D data from other PF-06882961 studies to provide 
recommendations o n dosing for par ticipan tswith vary ing degrees of hepatic impairment.
2.3.3. Overall Benefi t/Risk Concl usion
In line with the clinical profi le of marketed GLP -1Ragonists,11-13the most fre quently 
reported AEs with PF -[ADDRESS_118913] heart 
rate values within the normal range.  Based on current Phase 1 data wit h PF-06882961, a 
20mgdose is a nticipated to be well tolerated, even if plasma concentra tions are higher with 
hepatic impairmen t.  
Considering all availa ble clinical andnoncli nical data, the benefit- risk profile of 
PF-06882961 supports continued clinica l developm ent. Based on the safe ty profile of 
PF-0688 2961observ ed in clinical studies to date, the risk to the participants in this study  is 
deemed to be minimal. More detailed information about the known and expected benefits 

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page 21and risks and reasonabl y expected AEsof PF-068829 61 may  befound in the IBfor 
PF-
06882961, which i s the single ref erence safet y document (SRSD) for this study .
3.OBJECTIVES AND ENDPO INTS
Objectiv es Endpoin ts
Primary: Primary: 
 To compare the PK of PF -06882961 fol lowing 
administra tion of a single oral d ose in ad ult 
participants with v arying de grees of hepatic 
impairme nt relative to age -and body 
weight -matched participants without h epatic 
impair ment.Plasma: C max, AUC inf, AUC last,fu as data permit.
Secondary: Secondary: 
 To eva luate th e safety and to lerabilit y of a single 
oral do seof PF-06882961 wh en administered to 
adult participants with varying degrees of hepatic 
impairment and in age-and body wei ght-matched 
participants w ithout hepatic impairment. Assessme ntof treatment e mergent AEs, clinical 
laboratory abno rmalities, vital signs,ECG paramete rs.
Tertiary/Ex ploratory: Tertiary/Exploratory: 
 To compare additional PK param eters of 
PF-0688 2961 fo llowing administration of a single 
oral dose in adult partici pants with varyin g degree s 
of hepatic impairment and i n age-and body 
weight-matc hed parti cipants without hepatic 
impairment.Plasma: C max,u, AUC inf,u, AUC last,u, CL/F, CL u/F, 
Vz/F, V z,u/F, Tmax, t1/2as data permit.
4.STU DY DESIGN
4.1.Overall Design
This is a non-randomized, open- label,single -dose, parallel -coho rt, multicenter study to 
investigate the effect of v arying degrees of hepatic function on the plasma PK of
PF-06882961 after a sing le,oral 20mg dose administered in the fed state.  A total of 
approxim ately  24particip ants wit h vary ing degre esof hep atic function will be dosedin the 
study  as shown in Table 1. 
Table 1.Hepatic Functio n Categori es Based on Child -Pugh Score
Cohort Description Child -Pugh S core Number of 
Participan ts
1 Without h epatic im pairm ent Not Applicab le 6a
2 Mild hepati c impairment Class A (5 to 6 points) 6
3 Moderate hepatic impairment Class B (7 t o 9 points) 6
4 Severe hepatic impairment Class C (10 to 15 points) 6b
a.Additional participant smay bedosed to a maximum o f 8 participan tsto ensure mean age ±5years and 
mean body weight ±10kg of this cohort is aligned with the pooled average assessed when ≥75% of 
participants are d osed across the other [ADDRESS_118914] udy w ill dose only 4 participant sin this
cohort.

PF-06882961 
Protocol C3421014Final Protocol, 05 October 2020
PFIZER CONFIDENTIAL
Page 22Categorization of participants into Cohort 2-4, inclusive, will be done based on Child-Pugh 
scores determined, as described in Appendix 8 at the screening visit.  Participants will be 
dosed in a staged manner such that those with moderate and severe hepatic impairment (Cohorts 3 and 4) will be evaluated first.  Recruitment for participants with mild hepatic impairment (Cohort 2) will initiate when approximately 50% of the total participants in Cohorts [ADDRESS_118915] been dosed.  Participants without hepatic impairment (Cohort 1) will be recruited near the end of the study to match the average demographics (at a minimum, age and weight; and gender as much as practically possible) across the pooled Cohorts [ADDRESS_118916] be obtained before proceeding with recruitment for 
participants in Cohort 1 and Cohort 2.
Participants who prematurely discontinue before completing all assessments may be 
replaced, at the discretion of the principal investigator (PI) and sponsor study team.
The overall study design is summarized in Section 1.2 .  For individual participants, the total 
duration of participation from the screening visit to the follow-up visit will range from approximately 5 weeks (minimum) to approximately 9 weeks (maximum).
4.2. Scientific Rationale for Study Design
This study involves participants with varying degrees of hepatic impairment and participants
without hepatic impairment, matched for age as well as body weight (and gender as much as practically possible). A single dose of PF-[ADDRESS_118917] of hepatic impairment on human pharmacokinetics for 
compounds cleared in a similar manner to PF-06882961  mild hepatic impairment generally results in less than 2-fold increases in plasma exposure.
14  In 
the same group of compounds, moderate hepatic impairment results in less than 3-fold 
increases in plasma exposure; however, overall, very limited clinical data are available regarding the effect of severe hepatic impairment  
.
15-[ADDRESS_118918] the conditions for anticipated use of PF-06882961 in the target T2DM population.  Additionally, in study C3421001, variability based on geometric %CV for C
maxwas lower 
following administration with a high-fat meal (23% in the fed state, compared to 91% in the CCI
CCI
PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page 23fasted sta te).The a djusted g eometric mean C maxwas 57% lower (90% CI: 28%, 74%) in the 
fed state compared to t he fa sted state, w hile mean AUC infvalues were simil ar (approximately  
12% lower in the fed state [9
0% C I: -5%, 26%]).
In gen eral, par ticipants 
with normal hepatic fu nction (C ohort 1) will abstain from 
concomitant treatments, except for the treatment of adv erse events .  Howe veruse of selected 
limited prescription and non -prescription medications is perm itted (refer to Section 6.5 for 
details). COVID -[ADDRESS_118919] been incorporated to minimize the ri sks of 
COVID -19 related complications to participants and the study  site personnel.
P
articipants with impa ired hepa tic function (Cohort s 2, 3, and 4) are permitted to be on stable 
doses of 
background medications for the management of thei r concomitant medical 
condition( s) with some exclusions (Appendix 9 ).
The Child-P ugh class ification (CPC; refer toAppendix 8 ) will be used to define the 3 cohorts 
of partic ipantswith vary ing degrees of hepatic impairment.  This study will inclu de 
participants with mild (Child -Pugh Class A, Cohort 2),moderat e (Child -Pugh C lassB,
Coho rt3), and severe (Child -Pugh Class C, Cohort 4) hepatic impairment as well as 
demographic -matched control participants without hepatic impairment (Cohor t 1).  All 
[ADDRESS_118920] a previous history  of Grade 3 or 4 encephal opath y but are curre ntlyreceivi ng an 
intervention [for example: lactulose or lactitol, alone or in combination with rifaxi min, and/or 
neomy cin] to manage their encephalopathy -related signs and sy mptoms are eligible provided 
the on- treatment encephalopathy grading at the screening visit is Grade 2 or lower thereby  
[CONTACT_107075].  Ackn owledging the medical state of 
the population enrolled, certain eligibility  criteria for participants with hepatic impairment
a
re distinctly  different, with no spe cific exclusion of participants with Hepati tisB and 
Hepatitis C in Cohorts 2, 3, or 4.  
As stated i
n Section [IP_ADDRESS], there appears to be no clear effect of mild ren al im pairment on 
PF-
06882961 phar macokinetics . However, to enable a clear erassessment of the effec t of 
hepatic impairment onPF-06882961 disposition , participants will be excluded if there is 
concomitant clinical evidence of renal impairment, def ined as e stima ted glomerula r 
filtration 
rate (eGFR) <60mL/min.  
Both women of childbearing potential, as well as those who are of non-c hildbearing 
potential , will be enrolled given the availability  of em bryo fetal developmental (EFD) 
toxicity  studies wit h PF- 06882961.  Howe ver, as m arketedGLP -1R agonists are listed as 
contraindi cated in pregnancy , measures will be taken to limit the riskof pregnancy  in the 
female population enrolled (see SoA and Section 10.4).

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page 24The potential risk of exposure to PF- 06882961 in asexual partner of a male participant i n 
this study  via ejaculate is low, and therefore n o contraception (condom) use in male 
partici pants is warranted.  The calcu lated saf ety margin is ≥100-fold between the estimated 
partner exposure due to seminal transfer and the NOAEL for serious manifestat ions 
of 
developmental toxicity  in nonclinical studies.  The safet y margin of 100 -fold is based on 
apply ing a 10 -fold safet y factor for interspecies extra polation and a 10-fold safet y factor for 
susceptible populations .18
Banked Biospecimens will be collected and stored for further an alyses which may , for 
example, provide greater understanding of the study  interv ention.
4.3.Justification for Dose
Based on data available from the completed C3421001 study , a single dose of PF -06882961
20mg is expected to be safe and well tolerated and will provide data to meet the objectives 
of this study .  This dose selection al so tak esinto account safety  considerations for patients 
with vary
ing degre es of hepatic impairment in whom a n inc rease in plasma concentration of 
PF-06882961 may  be observed in this study.Based on current Phase 1 data, a 20 mg dose is 
anticipated to be well t
olerated.  Since the exposure of PF- 06882961 is approximately  
dose-proportional over the range of clini ca
l doses (up to single dose of 300 mg and up to 
120mgBID), the results of this study  can be extrapolated to understand the effect of hepatic
impairme nt on the PK of PF-[ADDRESS_118921] completed the study  if he/sh e has completed all phases of 
the study  including the follow -up visit vi a telephone contact s hown in the schedule of 
activities during the period of Day 28 to Day  32 (Day  30 ±2).
The end of the stud y is defined as the date of the follow -up visit via teleph one contact, shown 
in the schedule of activities, for the last participant in the trial globa lly.
5.STUDY POPULATION
This study  can fulfill its objectives only  if appropriate participan ts are enrolled.  The 
following eligibility  criteria are designed to sele ct participant s for whom participation in the 
study  is considered approp riate.  All relevant medical and nonmedical conditions should be 
taken into consideration when deciding whether a
particular participant is suitable for this 
protocol .
Prospective app
roval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol w aivers or exemptions, is not permitted .

PF-[ADDRESS_118922] y:
5.1.1. Parti cipants in All Cohorts
Age and Sex:
1.Male and female participants betw eenthe age s of18 (or the minimum 
country -specific age of consent if >18) and 70 years, inclusive, at the sc reening vi sit:
Refer to Appendix 4for reproductive criteria for male ( Section 10.4.1) and female 
(Section 10.4.2) participants .
Type of Participant and Disease Ch aracteristics:
2.Participants who are willing and able to compl y with all 
schedule d visits, tr eatment 
plan, laboratory  tests, lifesty le considerations, and other study  procedures.
Weigh t:
3.
Body  mass in dex (BMI) of 17.5 to 38.0kg/m2, inclusive ; and a total bo dy weight 
>50kg (110 lb), at the s creening visit; with a single re peat assessme nt of total body  
weight (and hence BMI), on a separate day permitted to assess eligibility , if needed . 
Informed Conse nt:
4. Capable of giving signed informed consent as described in Appendix 1 , which 
includes complianc e with t he requireme nts and restr ictions listed in the informed 
consent document (ICD) and in this protocol.
5.1.2. Additi
onal Inclusion Criteria for Participants without Hepatic Impairment 
(Cohort 1 Only )
1. At screening, no clinically  relevant abnormalities identi fied by  a detailed m edical 
histo ry, complete physical exami nation, including blood pressure (BP) and pulse rate
measurement, 12- lead ECG and clinical laboratory  tests, as assessed by  [CONTACT_103] -identifi ed central laboratory ;
2. At s creening, p articipants mus t meet t he demographic- matc hing criteria, including : 
A body weight that is 10
kg of the average of the pooled h epatic impair ment 
cohorts (Cohorts 2, 3, and 4), as provided b y the spo nsor;
An age that is ±5years of the average of the pooled hepatic impai rment coho rts 
(Cohorts 2, 3, and 4), as provided b y the s ponsor;

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page 26Attempts will be made to ensure that the male- to-female distr ibution in Cohort 1, 
is comparable, to that in the pooled hepatic impairmen t cohorts (Cohorts 2, 3, 
and4);
3.No known or suspected hepatic impa irment; i nclud ing at screening, meet allthe
following criteria, as assessed by  [CONTACT_456] -identifie d central lab oratory , with a 
single repeat permitted to assess eligibil
ity, if needed:
Alanine aminotransferase ( ALT) ≤ upper limit of normal (ULN);
Aspa rtate amin otran sferase (AST ) ≤ULN;
Total bilirubin ≤ULN;
NOTE: Participants with a history  of Gilbe rtsyndrome (and hence elevated total 
bilirubin) are eligible provided direct bilirubin l evel is ≤ ULN plus ALT and AST 
are ≤ULN plus alkaline phosphata se, hemoglobi n, a nd reticulocy te count are all 
≤ULN; 
Albumin ≤ULN;
Prothrombin time ≤ULN.
5.1.3. Additiona lInclusion Criteria for Participants with Impaired Hepatic Function 
(Coh orts 2, 3, and 4 Only )
1.Stable hepatic impairmen t that meets the criteria for Cla ssA, B, orCof the 
Child -Pugh classification (refer to Appendi x 8)with no clinically  significant change 
in disea se status within the 
28days prior to the screening visit, as docume nted by  [CONTACT_2416] ’s recent me dical hist ory (for example : no worsening clinical signs of 
hepatic impairment, no worsening of total bilirubin or prothrombin time (PT) by  [CONTACT_26813] 50% );
2.Stable concomitant medications for the management of individual pa rticipant s ’
medical history ; on a case-by- casebasis , with input from the s ponsor, participant s 
receiving fluctuating concomitant medica tion/treatment may  be considered if the 
underly ing disease is under contr ol;
3.Participant is willing and able to abide b ythe lifesty le guidelines describ edin 
Section 5.3 of this protocol.  

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page 275.2.Exclusion Criteria
Participants are excluded from the study  if any  of the fo llowing crit eria apply :
5.2.1. Participants in All Coh orts
Medical Conditions:
1.Any cond ition possib
ly affecting drug absorption (eg, prior bariatric surgery, 
gastrec tomy, ileal resection) ;
NOTE :Participants who have undergone cholecystectomy  and/or appendectomy are 
eligibl e for this study  as long as the sur gery occurred more than 6 months prior to 
Screening;
2. At s creening, participants with a positive result for human immunodeficiency  virus 
(HIV)antibodies, as assessed by  [CONTACT_3211] -identified central laboratory , with a singl e 
repeat permitted to asses s eligibi lity, if needed;
3.A diagnosis of type 2 diab etes m e llitus (T2DM) that is documented b y medical 
history ;
4.Personal or famil y history of med ullary thyroid carcinoma (MTC) or multiple 
endocrine neoplasia s yndrome t ype 2 (MEN2), or participan ts with suspected MTC 
per the investigator’s judgemen t;
5. O ther medi cal or psy chiatric condition including recent (within the past year) or 
active suicidal id eation/behavior or laboratory  abnormality  that may  increase the risk 
of study participation or, in the investigator’s ju dgment, make the participant 
inap
propriate fo rthe study ;
Prior/Conco mitant Therapy:
6.Use of prior/concomitant therapi[INVESTIGATOR_107058] 6.5 ;
Prior/Concurrent Clinical Study Experience:
7.Previous administration with an inv estigational drug within 30 days (or as determined 
by [CONTACT_19970]) or [ADDRESS_118923] used in t
his study  (whichever i s longer) ;
8.
Participants with know n prior partic ipation (ie, randomized and received at least
1dose of investigational product) in a stud y involving PF- 06882961; 

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page 28Diagnostic Assessments:
9. P articipants with ANY of the following abnormal ities in clinical labo ratory  tests at 
Visit [ADDRESS_118924], if de em
ednecessary:
HbA1c ≥
6.5%;
FPG ≥126 mg/ Dl;
eGFR<60 mL/min/1.73m2;
10.A positive urine drug test, for illicit drugs at screening , as assessed b y 
sponsor -identified central laboratory .  However, 
participants in Cohorts 2- 4, only , 
who have been medi cally prescri bed opi[INVESTIGATOR_858]/ opi[INVESTIGATOR_107059] o
f these drugs to the investigator at the Screening visit will be allowed to 
participate; 
NOTE :repeat urine drug testing is not permitted in this study ;
11. At sc reening orDay -1, a positive brea th alcohol test, as asse ssed using kits provided 
by [CONTACT_3211] -identified central laboratory , with a single repeat on a separate day
permitted to assess eligibility , if needed ;
12.A positive COVID -[ADDRESS_118925] atscreening ;
Other Exclusions:
13.Blood donation (e xcluding plasma donations) of approximately  1 pi[INVESTIGATOR_11731] (500 mL) or 
more wit hin [ADDRESS_118926] ;
14.History  of sensitivity  to heparin or heparin -induced thrombocy topenia, only  if heparin 
is used to flush intravenous catheter sused during s
erial blood col lections;
15.Unwil ling or unable to comply  with the cr iteria in the Lifesty le Considerations
section of this protocol;
16.Investigator site staff or [COMPANY_007] employ ees directl y involved in the conduct of the 
study, site sta ff otherwis e supervised b y the investigator, a nd their r espective family  
members.

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page 295.2.2. Additional Exclusion Criteria for Participants without Hepatic Impairment 
(Cohort 1 Only )
Participants presenting with anyof the following will not be include din the study :
1.Evidence of chronic liver dise ase including history of hepatitis, hepatitis B, or 
hepatitis C or evidence of an y of the following, as assessed b y sponsor -identified 
central laboratory , with a single repeat, permitted to assess eligibility , if needed :
HepatitisB virus,defined by  [CONTACT_107076] B surfa ce antigen (HBsAg);
NOTE :while not part of the tests assessed in this study , participant s with a 
previously  positive 
hepatitis B surface antibod yresult due to vaccination are 
deemed e ligible;
Hepati tis C infection, defined by  [CONTACT_107077] C anti body  (HCVAb) and
HCV ribonucleic acid (RNA);
2.History  of alcohol abuse or binge drinking a nd/or any  other illicit drug use or 
dependence within 6 months of Screening.  Binge drinking is defined as a pa ttern of 
5(mal
e)and 4 (female ) or more alcoholic drink s in about 2 hours.  As a general rule, 
alcohol intake should not exceed 14 units per wee k (1 unit = 8 ounces (240 mL ) beer, 
1 ounce (30 mL) of 40% spi[INVESTIGATOR_107060] 3 ounces (90 mL) of wine).
3. S creening supin e12-lead ECGdemonstrating QTc F interval >450 msec or a QRS 
interval >120 msec.  If QTcF exceeds 450 msec, or QRS exceeds 120 msec, the ECG 
should be repeated 2 more times and the average of the 3 QTcF or QRS values should 
be used to determ ine the partici pant’s el igib ilit y;
4.Screening s eated systolic blood pres sure (SBP) ≥140 mm Hg or diastolic blood 
pressure (DBP) 90mm Hg, following ≥[ADDRESS_118927].  If SBP is 
≥140 mmHg or DBP ≥90mm Hg, the BP assessment should be repeated 2 more 
times and the average of the 3BP values sh ould be used to determine eligibility ;
5.Use of chronic prescription medications within 7 days or 5 half-lives (whic hever is 
longer) prior to Day 1;
NOTE: Use of selected, limited prescription and non -prescripti on medications is 
permit ted (ref er to Section 6.5for details); 

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page 305.2.3. Additional Exclusion Criteria for Participants with Impaired Hepatic Function 
(Cohorts 2, 3, and 4 Only )
Participants presenting with any  of thefollowi ng willnotbe included in the study : 
1.Hepatic c arcinoma or hepatorenal s yndrome orlimited predicted life expectancy  
(defined as less than 1year in Cohorts 2 & 3 and less than 6 months for Cohort 4 
only);
2.A diagnosis of hepatic d ysfunction second ary to any acute ongoing hepatocellular 
process that is documented by  [CONTACT_9870] , phy sical examination, liver biopsy , 
hepatic ultrasound, computerized tomograph y scan, or magnetic resonance imaging 
(MRI) ;
3.
History  of surgery  that would b eexpected to a lter abs orption, distribution, 
metabolism, or excretion (ADME) properties of PF -06882961 (eg, status post 
porta -caval shunt surgery); 
NOTE: Participants with a transjugular intrahepatic portosy stemic shunt (TIPS) are 
permitted provided that they meet the Child-Pugh criteria;
4.History  ofgastrointestinal hemorrh age due to esophageal varices or peptic ulcers less 
than 4 weeks prior to Screening; 
5. S igns of clinicall y active Grade 3 or 4 hepatic encephalopathy  (ie,>Grade 2 Portal 
Systemic Encepha lopathy  score; refer to Appendi x 8);
6. Severe ascites and/or pleural effusion, except for those categorized in Cohort 4 who 
may be enrolled provided participant is me dicall y stable, per the investigators’ 
medical jud gment;
7. Participa nts who ha ve pre viously  receiv eda kidney , liver, or he arttransplant ;
8.Screening 
supi[INVESTIGATOR_050] 12-lead ECG d emonstrating a QTcF interval >4 70msec or a QRS 
interval >[ADDRESS_118928] rage of the 3 QTcF or QRS values should
be used to determine eligibility ;
9. At s creening, persistent severe, uncontrolled h ypertension; for example: seated SBP 
≥180 mmHg and/ or DBP ≥105 mmHg after ≥5-minute of seated rest, w ith a single 
r
epeat permit ted toassess eligib ility, if needed, at each of these 2 visits:
For participants with SBP ≥160 (and <179) mm Hg orDBP ≥100 (and 
<104) mmHg, the period between Screening and Day  -[ADDRESS_118929] stable BP 
by[CONTACT_2006] 1[refe r toSection 5.2.4];

PF-[ADDRESS_118930] >5x ULNon clinical laboratory  tests at screening, as 
assessed b y the spo nsor-identified central la boratory, with a sin gle repeat permitted to 
assess eligibility , if needed.
5.2.4. Criteria for Dosing on Day [ADDRESS_118931] satisfied allthe following 
criteria:
Breath alcohol test, us
ing kits provid ed by [CONTACT_64772]-identified centra l laboratory , on 
Day -1 is negative;
In women of childbearing potential, urine pregnancy  test on Day -[ADDRESS_118932] using supplies provided by  [CONTACT_456]
-identified 
centra llaboratory ;
Safety-relatedlaboratory  tests collected and anal yzed b ysites’ local laboratory  on 
Day -1, if performed at investigator discretion, upon review on Day [ADDRESS_118933] the 
participant to be in stable medical condition;
Cohort 1 and Cohort 2 only:Approval f r om the sponsor must be obtaine d before 
proceeding with dosing participants in either Cohort 1 or Cohort 2;
Cohorts 2 and 3 only:Participants must have measurement on Day 1 of 
SBP ≤159 mm Hg andDBP ≤99mm Hg ;
A single repeat assessment is permitted, to confirm that the a bove criterion is met 
[and in such cases, the repeat assessment overrides in itial results] ; 
Cohort 4 only :Partic ipants must have measurement on Day 1 of SBP ≤159 mm Hg 
andDBP ≤105 mm Hg;
A single repeat assessment is per mitted, to confi rmthat th e abovecriterion is met 
[and in such 
cases, the repeat assessment overrides initial results] .
5.3.Lifestyle Considerations
After confirmation of eligibility , participants will be instructed to maintain the guidelines 
described below for the duration of partic ipation in the study . 
5.3.1. Meals and Dieta
ry Rest rictions
Participants must abstain from all food and drink (except water) at least [ADDRESS_118934] 10hours prior to the 
collec tion of the pre dose PK sam ple;
Water may  be co nsumed as desired 
(ad lib itum);

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page 32While inpatient, all meals will be standardized as follows: 
On Day  1, following an overnight fast of at least [ADDRESS_118935].
There will be no
waterrestriction s prior to dosing.
Standa rd morning meal, lunch, afternoon snack , and evening meal (and an 
optional evening snack) will be provided at a similar clock time to the clock time 
when these meals are provided relati ve to dosing on Day 1while inpati ent(ie, 0H,
4H, 7H, 10H, and 14H);
The total daily  nutritional composition should be approximately  
55% carboh ydrate, 30% fat and 15% protein.  The nutritional macronutrient 
composition consumed by [CONTACT_107078], as much as 
practically  possible ;
The daily  caloric intake per participant should not exceed app roximately  
3200 kcal; 
The morning meal (matching 0H), afternoon snack, and optional evening snack is 
each envisioned to constitute 300 to 400 cal ories and a mac r onutrient composition 
of appro ximately  55% carbohy drate s, 30% fat and 15% protein;
Lunch and e vening meal each is envisioned to constitute less than 1000 calories;
Participants will refrain from consuming red wine, grapefruit, or 
grapefruit -related citrus fruits (eg , Sevill e oranges, pomelos, fruit juices) fro m 
7days prior to Day  1 and until colle ction of the final PK blood sample.  
5.3.2. Caffeine, Alcohol, and Tobacco
Participants will abstain from alcohol for 24hours prior to admission for i npatient 
stay (
plus have a negative breath alc ohol test on Day -1) and continue abstaining from 
alcohol until collection of the 
final PK blood sample ;  
Consumption of caffeinated drinks and tobacco (or nicotine containing products) is 
permitted during par ticipation in the study ; however,there may  bea need for brief 
interruption while at the site, depending on local site policy .

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page 335.3.3. Activity
Participants will notbe permitted to engage in ph ysically strenuous exercise (for 
example: heavy  lifting, weight traini ng, calistheni cs, and aer obics)within 48 hours 
before each blood samp le collection for clinical laboratory  tests while participating in 
the study ; phy sical 
activity  at an individual participant’s norm al pace is permitted.
5.3.4. Contraception
The investigator or his or her de signee , inc onsu ltation with t he participant , will conf irm that 
the participant has selected an appropriate method of contraception for the in dividual 
participant and his or her partner( s) from the permitted list of contraception methods (s ee 
Appendix 4 Section 10.4.4 )andwillconfirm that the participant has been instructed in its 
consistent and correct use.  At time points indicated in the sched ule of activi ties(SoA), the 
investigator or designee will inform the participant of the need to use highly  effective 
contraception consist ently  and correctl y and document the conversation and the participan t’s 
affirm ation in the participant ’schart(participant sneed to affirm their con sistent and correct 
use of at least 1 of the selected methods of contraception).  In addition, the investig ator or 
designee will instruct the participant to call immediately  if the sele cted contracept ion method 
isdiscontinued or i f pregnancy  is known or s uspected in the participant or partner.
5.4.Screen Failures
Screen failures are defined as participants who con sent to participate in the clinical study  but 
are not subsequently  dosed on Da y1.  Screen fa ilure data ar e collected and re main as source 
with only  a limited set reported inthe clinical database.
In this study ,participant s may  be re -screened only after contact [CONTACT_107079] .  This is 
permitted when, due to logis tical const raints , the ma ximum perio d betweens c reening visit 
and Day 1, of 28days,is exceeded.  In addition, for parti cipants in Cohorts 2-4, inclusive, 
only, re-screening may  be appropriate following mild intercurrent illness after the condition 
has resolved.  Insuch cases, a ll screenin g procedures must be repeated and the participant 
assigned a new 8 -digit study -specif ic identification (SSID) number.  Participants must be 
deemed to meet all the eligibility  criteria under the new 8 -digit SSI D before progressing to 
Day 1.  Reconsent is re quired.
6.STUDY INTERVENTION
Study  inter vention is defined as an y investigational intervention(s), marketed p roduct(s), 
placebo, medical device(s) , or study  procedure(s) intended to be administered to a study  
participant according t othe study  protocol.
For the purposes of this protocol, study  intervention refers to PF -06882961 .

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page 346.1.Study Intervention(s) Administered
PF-[ADDRESS_118936] as 
outlined in Section 5.3.1 (Meals and Dietary  Restrictions).  The participants will then r eceive 
IPat approximately  08:00 hours (plus or minus 2 hours) on Day 1.  Investigator sit e 
personnel will administer IPwit
h ambient tempe rature wat erto a total volume of 
approximately 120 mL.  Participants will swallow the IPwhole, and will not manipul ate or 
chew th e IPprior to swallowing .  
6.2.Preparation/Handling/Storage/Accountability
1.The investigator or designee must con
firm appropriat etemperatu reconditions have 
been maintained during tra nsit for all study  intervention sreceived and an y 
discrepancie s are reported and resolved before use of the study  intervention. 
2.
Only participants enrol led in the study  may  receive stud yintervention and only  
authorized site staff may supply  or administer study  intervention.   All study 
interventions must be stored in a secure, env ironmentally  controlled, and monitored 
(manual or automated recording) area in accordance with the labeled st orage 
condition
swith acce sslimited to the investigator and authorized site staff.  At a 
minimum, daily  minimum and maximum temperat ures for all site storage locations 
must be documented and available upon request.  Data f or nonworking days must 
indicate the minimum and maximum te mperaturessince pre viousl y documented for 
all site storage locations upon return to business.
3.Any excursio ns from the st udy intervention label storage conditions should be 
reported to [COMPANY_007] upon discovery  along with an y actions t aken.  The sit eshould 
active lypursue option s for returning the study intervention to the storage conditions 
described in the labeling, as soon a s possible.  Once an excursion is identified, the 
study  intervention must be quarantined and not used until P fizer provides permission 
tousethe study  intervention.  Specific deta ils regarding the definition of an excursion 
and information t
he site should report for each excursion will be provided to the site 
in the IP manual .
4.Any storage conditions stated in th eSRSD will be s uperseded by[CONTACT_107080].
5.Study  interventions should be stored in their original conta iners.

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page 356.The investigator, institution, or the head of the medical institution (where applic able) 
is responsible for stud y intervention acco untability , reconciliation, and record 
maintenance (ie, receipt, reconciliation, and final disposition records) , such as the 
IPAL or sponsor -approved equivalent .All study  intervention swill be accounted for
using a study  intervention accou ntabilit y form/ record.   
7.
Furtherguidance and information for the final disposition of unused study  
interventions are provided in the IP manual .  All destruction must be adequately  
documented.  If destruction is authorized to take place at the invest igatorsite, the 
investigator must ensure that the m aterials are destroy ed in compliance with 
applicable environmental regulations, institu tional policy ,and any  special instructions 
provided b y [COMPANY_007].
Upon identification of a product complaint, notify th e spons or within 1 business day  of
discovery  as described in the IP Manual .
6.2.1.
Preparation and Dispensing
Within this protocol, preparation re fers to the in vestigator site activities performed to make 
the study  intervention ready  for administration or dispens ing to the participan tby [CONTACT_107081].  Dispensi ng is defined as the prov ision of study  intervention , concomitant treatments, 
and accom panying inform ation by  [CONTACT_22806](s) to a healthcare provider, 
participant in accordance with this protoc ol.  L ocal health authority  regu la tions or 
investiga tor site guidelines may  use alternative terms for these activities.
Study  intervention will be prepar ed by [CONTACT_107082].  
Table ts will be prepared at the CRU in the individual dosing con ta
iners by 2operato rs, 1 of 
whom is an appropriatel y qualified and experienced member of the stud y staff ( eg, ph ysician,
nurse, ph ysician’s assistant, nurse practitioner, pharmacy  assistant/techni cian, or pharmacist).  
The tablet swill be provi ded in unit dos e containers and labeled in accordance wi th [COMPANY_007] 
regulations and the clinical site’s labeling require ments. 
6.3.Measur es to Minimize Bias: Randomization and Blinding
6.3.1. Allocation to Study I nterven tion
This is an open label, non-
randomized study .  Followin g completion of info rmed consent at 
the screening visit, each participant will be assigned a single [ADDRESS_118937] each participant’s unique number assigned in chronological 
order of when informed consent is obtained. Separately , prior to dosing on Day  1, each 
participant will be as signed a 4- digit number co nsisting of site number (1stdigit), cohort 
(2nddigit) and ch ronological order of dosing, at a given sit e (3rdand 4thdigit).  

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page 366.4. Study Intervention Compliance
When th e individual dose for a participant is prepared from a bulk sup ply, the preparation of 
the dose will be confirmed by  a seco
nd qualified me mber of the studysite staff.
When participants are dose d at the site, they  will receive study  intervention directly  from the 
inves tigator or designee, under medical supervision.  The date and time of each d ose 
administered in the clinic wil lbe recorded i nthe sourc e docu ments and rec orded in the CRF.  
The dos e of stud y intervention and study participant identification will be confir med at the 
time of dosing b y a member of the stud y site staff other than the person administering the 
study  intervention. Study site pe rsonne l will examin eeach participant’s mouth to ensure that 
the study  intervention was ingested.
6.5.
Concomitant Therapy
All concomitant treatments taken during the study must be recorded with indica tion, daily  
dose, and start and st op dates of adm inistration . Allparticipants will be questioned about 
concomitant treatment at each clinic visit.
Participants with Hepatic I mpai rment will be allowed to be on certain concomitant 
medications that have bee n prescribed.  An y concomitant med ications may be administer ed
in the morning of Day [ADDRESS_118938] be captured in t
he case report for m (CRF ).
Phosphate binder s, antacids, and bile acid binding resins (eg, cholesty ramine, colestipol) 
must not be administered within [ADDRESS_118939] udy. See Appendix 4for hormonal contraceptives that are permitted in
this study .
6.5.1.
Participants without Hepatic Impairment (Cohort 1, Only)
In general, parti cipants in Cohort 1 will abstain fro m all concomitan t treatmen ts, except for
the treatment of 
AEs.  Of note , the following restrictions:
Acetaminophen/paracetamol may  beused at doses of ≤ 1 g/day ;
Herbal supplements must be discontinued at least [ADDRESS_118940];

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page 37Limit ed use of p rescription and nonprescription medications t hat are not believed to 
affec t the overall results of the stud y ma y be permitted on a case b y case basis 
after
approval b y the sponsor study  team.
6.5.2. Participants with Impaired Hepatic Func tion (Cohorts 2, 3, and 4)
Participants are permitted to be on stable doses of background medications for the 
management of their co ncomitant medical condition(s).  Whenever possible , attempts must 
be made to notalter the doses and regimens of the concomi tant medicatio ns after Da y [ADDRESS_118941].
Particip ants on certain medications, at the screening visit, are exclu dedfrom the study
(see Appen dix 9 for details regarding prohibited prior/conco mitant medicati ons).
6.5.3. Rescu e Medicine
There is no rescue therapy  to rev erse the AEs observed with PF-06882961; standard medical 
suppo
rtive care must be provided to manage the AEs. 
6.6. Dose Modification
Dose modification of PF -06882961 is not allowed.
6.7.Interve ntion A fter the End of the Study
No interventi on will be provided to study  participants at the en d of the study .
7.DISCONTINUATION OF S TUDY INTERVENTION AN D PARTICIPANT 
DISCONTINUATION/WITH DRAWAL
7.1.Discontinuation of Study Intervention
Since this is a single -
dose study , this section is notapplicable.
7.2.Participant Discontinuation/ Withdrawal
From the Study
A participant may  withdraw from the study  at an y time at his/her own request.  Reasons for 
discontinuation from the study  include the following:
Refused furth er follow -up;
Lost to follow -up;
Death ;
Study  terminated by  [CONTACT_3211] .
Atthe time of discontinuing from the stud y, if possible, an ear ly discontinuation visit should 
be conducted
.See the SoA for assessments to be collected at the ti me of study  
discontinuati on and follow -up and for any  further evaluations that need to be comple ted. 

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page 38If a participant withdraws fro m the study , he/she may  request destruction of any  remaining 
samples taken and not tested, and t he investigator must docume nt any  such req uests in the 
sitestudy  records and notify  the sponsor a ccordingly .
If the partici pant withdraws from the study  and al so withdraws consent (see Section
7.2.1) 
for disclosure of fu
ture information, no further e valuations shoul d be performed and no 
additional data should be collected.  The sponsor may  retain and continue to use an y data 
collected before such withdrawal of consent.
Lack of completion of all or an y of t he withdrawal/ea rly termination procedures will not be 
viewed as protocol deviations so long as the participant ’s safet y was preserved.
7.2.1. Withdrawal ofConsent 
Participant s who request to discontinue receipt of study  intervention will remain in the study  
and must continue 
to be followed f or protocol- specified follow -up procedures.  The onl y 
exception to this is when a participant specificall y withdraw s consent for any  further contact 
[CONTACT_107083].  Participant s should notify the investig ator in writing of the de cision to 
withdraw consent from future follow
-up, whenever p ossible.  The withdrawal of consent 
should be explained in detail in the medical records by  [CONTACT_093], as to whether t he 
withdrawal i sonly from f
urther receipt of study  intervention or als o from study  procedures 
and/or posttreatment study  follow -up, and entered on the appropriate CRF page.  In the event 
that vital status (whether the participant is alive or dead) is bein gmeasured, pub licly 
avail ableinformation sho uld be used to determine vital status only  as appropriately  directed 
in accordance wi thlocal law.
7.3.Lost to 
Followup 
A participant will be considered lost to follow- up if he or she repeatedl y fails to return f or 
scheduled vi sits and is unabl e to be contac ted b y the study  site.
The following actions must be taken if a participant fails to return to the clinic for a required 
study  visit:
The site must attempt to contact [CONTACT_107084] v isit as 
soon as possible a nd
counsel the parti cipant on the importance of maintaining the 
assigned visit schedule and ascertain whe ther or not the participant wishes to and/or 
should continue in the study ;
Before a parti cipant is deemed lost to follow -up, t he investigato ror design eem ust 
make every  effort to regain contact w ith the participant (where possible, 3 telephone 
calls and, ifnecessary , a certified letter to the participant’s last known mailing 
address or local equivalent methods). These contact [CONTACT_107085]’s medical record ;

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page 39Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study. 
8.STUDY ASSESSMENTS AND PROCEDURES
The investigator (or an appropriate delegat eat the invest igator site ) mustobtain a sign ed and 
dated ICD before p erforming an y stud y-specific procedures.  
Study  procedures and their timing are summarized in the SoA . Protocol waivers or 
exemptions are not allowed.
Safety  issues should be discussed witht he sponsor imm ediately  upon occu rrence or 
awareness to determine whether the participant should con tinue or discontinue study  
intervention.
Adherence to the study design requirements, including those specified in the SoA, is essential 
and require d for stud y conduct .
All screening evaluations must be completed and reviewed to conf irm that potential 
participants meet all eligibility  criteria. The investigator will maintain a screening log to 
record deta ils of all part icipants sc reened and to confirm eligibility  or re cord r easons for 
screening failure, as applicable.
Participants wi llbe screened within 28 days prior to administration of the study  intervention
to confirm that they  meet the study  populatio ncriteria for t he study . If the time between
screening and dosi ng exc eeds 28 days as a result of unexpected delay s (eg, delay ed drug 
shipment), then participants do not require rescreening if the laboratory  results obtained prior 
to first dose administrat ion meet eligi bility  criteria.
Every  effort s hould be made to ensure t hat protocol -required tests and procedures are 
completed as 
described.  However, it is anticipated that from time to time there may  be 
circumstances outside the control of the investiga tor that may  make it unfea sible to perform 
thetest.  I n these ca ses, t he investigator must take all steps necessary  to ensure the sa fety and 
well-being of the participant
.  When a protocol -required test cannot be performed, the 
investigator will document t he reason for t he missed te stand an y correct ive and preventive 
actions that he or she has taken to ensure that required processes a re adhered to as soon as 
possible.  The study  team must be informed of these incidents in a timely  manner.
ECGs and vital si gn assessments (pulse rat e and BP) should be collected prior to any  blood 
draw. Ifan IV catheter is utilized for blood sample co llections, ECGs and vital sign 
assessments ( pulse rate and BP) should be collected prior to the insertion of the cathe ter.
Forsamples being collected and shipped, detaile d collection, processing, storage, and 
shipment instructions and contact [CONTACT_19987] .

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page 40The total blood sampling volume for indivi dual par ticipant s in t his study  is approximately  
175mL.  The actual collectio n times of blood sampling may
 change.  Additional blood 
sample s may  be taken for safet y assessments at times specified b y [COMPANY_007], provided the total 
volume taken during the study does not exceed 550 mLduring an y period of 60 conse cutive 
days.
To prepare f or study  participation, participant s will be instructed on t heinformation in the 
Lifesty le Considerations andConcomita nt Therapy sections of the prot ocol.
8.1.Efficacy Assessments
NotApplicable .
8.2. Safety Asses sments
Planned time points for all safety  assessme nts are provided in the SoA.  Unsche duled clinical 
laboratory  measurements may  be obtained at any  time during t he stud y to ass ess any  
perce
ivedsafety  issues.
8.2.1. Physical Examinations
Acomplete physical examination will include , at a 
minimum, head, ears, eyes, nose, mouth, 
skin, heart and lung examinations, ly mph nodes, and gastrointestinal, musculoskeletal, and 
neurological s ystems . 
A limited physical examination will include, at a mi nimum, assessments of general 
appearance, the resp iratory  and cardiovascular s ystems, and participant -reported symptoms.
Physical examinations may  be conducted by  a ph ysician, trained phy sician's ass istant, or 
nurse practitioner a s acceptable according to local regulation. 
Height and weight will also be measured and recorded as per the SoA.  For measuring 
weight, a scale with appropriate range and resolution is 
used and must b eplaced on a stable, 
flat surf ace. Participant s must r emove shoes, bulky layers of clothing, and jackets sothat 
only light clothing remains.  They  must also remove the contents of their pockets and remain 
still during measurement of weigh t. 
8.2.2. Vital Signs
Blood pres sureand pulse rate will be measured as defined in the Schedule of Activ ities .  
Additional collection times, or changes to collecti on times of blood pressure and pulse rate 
will be permitted, as necessary , to ensure appro priate coll ection of safet y dat a.
Single, seated BP/pulse rate will be measured with the participant ’s arm suppor ted at 
the level of the heart, and recorded to the ne arest mmHg, following a rest of 
≥5minutes ;

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page 41Same arm (preferabl y the dominant arm) will be used for BP/pulse rate assessment 
throughout the stud y;
BP/pulse rate assessment should not be taken from the ar m with an IVcatheter, if 
placed;
Participants should be instructed notto speak duri ng BP/pulse rate measurements.
The same properl y sized and calibrated BP cuff will be used to measure BP each time.  The 
use of an automated device for measuring BP and pu lse rate is acceptable; however, when 
done manuall y, pulse rate will be measured in t he brachial/radial artery  for at least 
30seconds.  When the timing of these measurements coincides with a blood collection, BP 
and pulse rate should be obtained prior to the nominal time of the blood collection. 
Additional collection times, or changes to collection times, of BP and pulse rate will be 
permitted, as necessary, to ensure appropriate collection of safety  data.
[IP_ADDRESS]. Temp erature
Body temperature will be measured at the timepoints listed in the SoA .  No eating, drinking, 
or smoking is allowed for [ADDRESS_118942] 12-l ead ECGs utilizing limb leads (with a 10 second rh ythm strip) should be 
collected at times specified in the SoA section of this protocol using an ECG machine that 
automatically  calculates the h eart rate and measures PR, QT, and QTc and QT cF intervals
and QRS complex .Alternative lead placement methodology  using torso le ads 
(eg,Mason
-Likar) is not recommen ded given the potential risk of discrepancies with ECGs
acquired using standard limb lead placement. All scheduled ECGs should be perf ormed after 
the participant has rested quietly  for at lea st 10minutes in a supi[INVESTIGATOR_107061]. 
To ensure safet y of the par ti
cipants, a qualified individ ual at the investigator s ite will make 
comparisons to baseli ne measurements.  Additional ECG monitoring w ill occur if a) a 
postdose QTc Finterval is increased by  ≥60 msec from the baseline andis >450 msec ; or 
b)an absolute Q TcFvalue is ≥
500msec for an yscheduled ECG.   If eithe r of these conditions 
occurs, then [ADDRESS_118943] hourly  until QTc F
values from 2 successive ECGs fall below the threshold value that triggered the repeat 
measurement.

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page 42If a) a postdose QTc Finterval remai ns ≥60msecfrom the baseline andis >450msec; or 
b) an absolute QTcF value is ≥500 msecfor an y scheduled ECG for greater than 4 hours (or 
sooner ,at the discret ion of the investigator) ;or c) QTcFintervals get progressively longer, 
the participant should undergo continuous ECG monitoring.  A cardiologist should be 
consulted if QTc intervals do not return to less than the criterion listed above after 8 hours of 
monitoring (or sooner ,at the discretion of the investigator).
In some cases, it may  be appropri ate to repeat abnormal ECGs to rul e out improper lead 
placement as contributing to the ECG abnormality.  It is important that leads beplaced in the 
same positions each time in order to achieve precise ECG recordings.  If a machine -read 
QTcFvalue is prolonged, as defined above, repeat mea surements may  not be necessary  if a 
qualified medical provider’s interpretation determines that the QTcF values are in the 
acceptable range.
ECG values of potential clinical concern arelisted in Appendix 7.
8.2.4. Clinical Sa fety Laboratory Assessments
See Appendix [ADDRESS_118944] any  
clinically  relevant changes occurring during the stu dy in the AE section of the CRF. 
Clinically  significant abnormal la boratory  findings are those which are not associated with 
the underl ying disease, unless judged by  [CONTACT_78259]'s condition.
All laboratory  tests with values consider ed clinically  significantl y abnorm alduring 
participation in the study  or within [ADDRESS_118945] dose of study  intervention should be 
repeated until the values return to normal or baseline or are no longer considered clinically  
significant b y the inv estigator or medical monitor.
If such values do not return to normal/baseline within a period of time judged reasonable by  
[CONTACT_093], the etiology  should be identified and the sponsor notified.
See Appendix 6f
or suggested actions and follow - up assessments in the event of potential 
drug-induced liver injury.

PF-[ADDRESS_118946] be captured on the AE C RF with specific details captured 
on the HAE Form CRF.  For the definition of a hypogl ycemic epi[INVESTIGATOR_95461] y 
categorization see Section [IP_ADDRESS] below .
[IP_ADDRESS]. Definition and Severity of Hypoglycemi c Adverse Event (HAE )
The investigator must assess the glu cose values reported by  [CONTACT_107086] , as well as 
any signs or s ymptoms reported by  [CONTACT_107087].
HAE is defi ned as one of the following :21
a.Asymptomatic hy poglycemia: An event not accompanied b y typi[INVESTIGATOR_107062] a glucose value of <70 mg/dL (3.9 mmol/L ) using ei ther glucometer 
(finger stick bl ood gluco se) at 
the study  site or sponsor -identifie d central laboratory  
(plasma glucose ).
b.Documented s ymptomatic hy poglycemia: An e vent during which t ypi[INVESTIGATOR_107063] E are accompanied with a glucose value of <70 mg/dL (3 .9mmol/L), using 
gluco meter at the stud y site or sponsor identified central labor atory , and the clinical 
pi[INVESTIGATOR_107064], subcutaneous gluc agon, or IV 
glucose .
c.Proba ble sy mptomatic hypogl ycemia: An event during which sy mptoms of HAE are 
not a ccompani ed by a glucose determi nation but was presumabl y cause d by a glucose 
concentration of < 70mg/dL (3.9 mmol/L), and the clinical pi[INVESTIGATOR_107065], subcutaneous glucagon, or IV glucose.
Each ep isode of HAE must be ca tegorize d with re spect t o sever ity.  In order to characteri ze 
the event as severe, all [ADDRESS_118947] be met:
1.The participant was un able to treat him/herself.  Neurologic i
mpairment, and not the 
age of the participant, is the explanation for wh y the pa rticipant coul d not t reat 
him/herself and required the a ssistance of another person.

PF-[ADDRESS_118948] 1of the followi ng neurologica l symptoms:
Memory  loss;
Confusion;
Uncontrolled behavior;
Irrational behavior;
Unusual difficulty  in awakening ;
Suspect ed seiz ure;
Seizure;
Loss of consciousness .
3.
Either:
If blood glucose was measu red and was ≤54 mg/dL (2.7 mmol/L) using 
glucometer (or ce ntral laboratory ); or
If blood glucose was not measured, the clinical manifestations were reversed by  
[CONTACT_107088] , subcu taneous glucagon, or IV glucose.
Events that do not meet all the criteria above for severe HAE are characterized as mild or 
moder ate in severity .
8.2.7. Pregnancy Testing
Pregnancy  tests may  be urine and/ or serum tests, but must have a sensiti vityof at le ast 
25mIU/mL.  Pregnancy  tests will be pe rformed in WOCBP at the times listed in the SoA .  
Following a negative pregnancy  test result at screening, appropriate contraception must be 
commenced and a second negative pregn ancy test re sult wi ll be required at the baseline visi t 
prior the participant ’sreceiving the study  intervention .  Pregnancy  tests will also be done
whenever 1 menstrual cycl e is missed during the active treatment period (or when potential 
pregnancy  is oth erwise suspe cted) a nd at the end of the study .  Pregna ncytests may  also be 
repeated if requested b y IRBs/ ECs or if required by [CONTACT_427].  If a urine test cannot 
beconfirmed as negative (eg, an ambiguous result), a serum pregnancy  test is requir ed. In 
such cases, the participant must be excluded if the serum pregnancy  result is positive .

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page 458.3.Adverse Events and Serious Adverse Events
The definit ions of an AE and an SAE can be found in Appendix 3.
AEswill be rep orted b y the par ticipant (or, when appropriate, b y a caregiver, surrogate, or 
the participant's leg ally authorized representative).
The investiga tor and an y qualified des ignees are responsi ble for detecting, documenting, and 
recording events that meet the definitio n of an AE or SAE and remain responsible t o pursue 
and obtain adequate information both to determine the outcome and to assess whether the 
event meets the criter ia for classificati
on as an SAE or caused the participant to discontinue 
thestudy  intervention (seeSection 7.1). 
Each pa rticipant will be questioned about the occurre nce of AEs in a 
nonleading manner.
In addition, the investigator may  be requested by  [CONTACT_19989] y to obtain sp ecific fo llow-up
information in an expedited fashio n.
8.3.1. Time Period and Frequency for Collecting AE and SAE Information
The time period for activel y eliciting and collecting AEs and SAEs (“active collection
period”) for each participant begins from the time the 
participant provides informed consent, 
which is obtained before the participant ’s participation in the study  (ie, before undergoing 
any study -related procedure and/or receiving study  intervention ), th
rough and including a 
minimum of [ADDRESS_118949] SAE Report Form.
Investigators are not obligated to a ctivel y seek A
E or SAE after the participant has concluded
study participation . However, if the investigator learns of an y SAE, including a death, at an y 
time after a par ticipant has completed the study , and he/she considers the event to be 
reasonabl y related to the st udy intervention, the investigator must prom
ptly report the SAE to 
[COMPANY_007] using the CT SAE Report Form .

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page [IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety
All SAEs occurring in a partic ipant during t he active collection period as described in 
Section
8.3.[ADDRESS_118950] SAE Report Form immediately  upon 
awareness and under no circumstance shou
ld this e xceed 24 hours, as indicated in 
Appendix 3. The investigator will submit any  updated SAE dat a to the sponsor within 
24hours of it being available.
[IP_ADDRESS]. Recording Nonserious AEs and SAEs on the CRF
All no nserious AEs and SAE s occurring in a participant during the active collection period, 
which begins afte r obtaining informed consent as described in Section 8.3.[ADDRESS_118951] on the CRF all directly  observed and all spontaneously  reported 
AEs and SAEs reported by  [CONTACT_2299].
8.3.2. Method of Detecting AEs and SAEs
The method of rec ording, evaluating, and assessing causality  of AE sand S AEsand t he 
procedures for completing and transmitt ingSAE reports are provided in Appendix 3.
Care wi ll be taken not to introduce bias when detecting AEs an
d/or SAEs.  Open -ended and 
nonleading verbal questioning of the p artici pant is the preferred method to inquire about 
AEoccurrences.
8.3.3. Follow -up of AEs and S AEs
After the initial AE/SAE report, the inves tigator is required to proactivel y follow each 
particip
ant at subsequent visits/contacts. For each event, the investiga tor mu st pursue and 
obtain adequate informati on until resolution, stabilization, the event is otherwise explained, 
or the participant is lost to follow -up (as defined in Section 7.3).
In general , follo
w-up information will include a des cription of the event in sufficient detail to 
allow for a complete medical assessment of the c ase and independent determination of 
possibl e causality .  An y information relevant to the event, such as concom itant med ication s 
and illnesses, must be provided. Inthe case of a participant death, a summary  of available 
autopsy  findings must be submitted as soon as possible to [COMPANY_007] Safety . 
Further information on follow -up procedures is gi ven in Appendix 3.
8.3.4. Regulatory 
Reporting Requirements for SAEs
Prompt notificat ion by  [CONTACT_11012] a n SAE is essential so that legal 
obligations and ethical responsibilities towards the safety of participants and t he safet yof a 
study intervention under clinical in vestigation are met.

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page 47The sponsor has a legal res ponsibility  to notify  both the local regulator y authority  and other 
regulatory  agencies about the safet y of a stud y intervention under clinical investigation . The 
sponsor w ill comply  with country -specific re gulatory  requirements relating to safet y 
reporti ng to the regulatory  authorit y, IRBs/ECs, and investigators.
Investigator safety  reports must be prepared for S[LOCATION_003]R saccording to local regulatory  
requirements and sponsor p olicy  and forwarded to i nvestigator s as necessary .
An investigator who receives S[LOCATION_003]Rs or other specific safet y information (eg, summary  or 
listing of SAEs) from the sponsor will review and then file it along with the SRSD(s) for the 
study and will notify  the IRB/EC, if appropria te accordin g to local requirements.
8.3.5. Exposure During Pregnan cy or Breastfeeding, and Occupational Exposure
Exposure to the 
study  intervention under stud y during pregnancy  or breastfeeding and 
occupational exposure are reportab le to P fizer Safety  within [ADDRESS_118952] igator 
awareness.
[IP_ADDRESS]. Exposure During Pregnancy
An EDP occurs if: 
A female participant is found to be pregnant while receiving or after discontinuing 
study  intervention .
A female is 
found to be pregnant while being expose d or having been expose d to 
study  intervention due to environmental exposure. Belo w are examples of 
environmental exposure during pregnancy : 
A female family  member or healthcare provider reports that she is pregnant after 
having been expo sed to the study intervention by [CONTACT_78262], inhalat ion, or skin 
contact .
The investigator must report EDP to [COMPANY_007] Safety within 24 hours of the investigator’s 
awareness, irrespective of whether an SAE has occurred. The i nitial information submitted 
should include the a nticipated date of delivery  (see be lowfor information related to 
termination of pr egnancy). 
If EDP occurs in a participant or aparticipant’s pa rtner, the investigator must report 
this information to Pfize r Safety on the CT SAE Report For m and an EDP 
Supplemental F orm, regardless of wheth er an SAE has occurred. Details of the 
pregnanc y will be collected after the start of stud y intervention and u ntil Day 28.

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page 48If EDP occurs in the setting of environmental exposure, the investigator must re port 
information to [COMPANY_007] Safety  using the CT SAE Rep ort Form and EDP Supplemental 
Form. Since the exposure information does not pertain to th e participant enrolled in 
the study , the informat ion is not recorded on a CRF; however, a cop y of the 
completed CT SAE Re port Fo rm is maintained in the investigato r site file.
Follow -up is conducted to obtain ge neral information on the pregnancy  and its ou tcome for 
all EDP reports with an unknown outcome. The investigator will follow the pregnancy  until 
completion (or until pregna ncy termination) and notify  [COMPANY_007] Saf ety of the outcom e asa 
follow -up to the init ial EDP S upplemental Form. In the case of a live birth, the structural 
integrit y of the neonate can be assessed at the time of birth. In the event of a ter mination, the 
reason(s) for termination should be s pecified and, if cli nically  possible, the struct ural 
integrit y of the terminated fetus should be assessed by  [CONTACT_4692] (unless 
preprocedure test findings are conclusive for a congenital anoma ly and th
e findi ngs are 
reported).
Abnormal pregnan cy outcomes are considered SAEs. If the outcome of the pregnancy  meets 
the criteria for an S A
E(ie, ectopic pregnancy , spontaneous abortion, intrauterine fetal 
demise, neonatal death, or congenital anomal y in a li ve-born baby, a terminated fetus, an 
intrauterine fetal demise , or a neonatal death), the investigator should follow the procedures 
forreporting SAEs. Additional information about pregnancy  outcomes that are reported to 
[COMPANY_007] Safety  as SAEs fol lows: 
Spontaneous abortion includ ingmiscarriage a nd missed abortion;
Neonatal deaths that occur w ithin [ADDRESS_118953] 
to causality , as SAEs. In addition, infant deaths after 1 month should be reported as 
SAEs when th
e investi gator a ssesses the infant death as related orpossibly  related to 
exposure to the study  intervention. 
Additional information regarding t he EDP may  be requested by  [CONTACT_456]. Further 
follow -up of birth outcomes will be handled on a case- by-case basis (e g, follow-up on 
preterm infants to identif y developmental dela ys). In the case of paterna l exposure, the 
investigator will provide the
participant with the Pregnant Partner Release of Information 
Form to deliver to his partner.  The investigator must docu ment in the source documents that 
the part icipant was given th e Pregnant Partner Release o f Information Form to provide to his 
partner.
[IP_ADDRESS].
Exposure During Breastfeeding
An exposure during breastfeeding occurs if: 
A female participant is found to be breastfee ding wh ile receiving or after 
discontinuin g study intervention .

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page 49A female is found to be br eastfeeding while being exposed or having been exposed to 
study  intervention (ie, environmental exposure). An example of environmental 
exposure during breas tfeeding is a fe male family  member or healthcare pr ovider who 
reports that she is breastfeeding after having been exposed to the study  intervent ion 
by [CONTACT_19991].
The investigator must repo rt exposure during breastfeeding to [COMPANY_007] Safety w ithin 24 hours 
of the investigator’s awareness, irr espective of whether an SAE has occurred.  The 
information must be reported using the CT SAE Report Form.  When exposure during 
breastfeeding occurs in th
e setting of environmental exposure, the exposure i nformation does 
not pertain to the participant enro lled in the study , so the information is not rec orded on a 
CRF. However, a cop y of the compl eted CT SAE Report Form is maintained in the 
investigator sit e file.
An exposure during breastfeeding report is not creat ed when a [COMPANY_007] drug specificall y 
approve d for use in breastfeeding women (eg, vitamins) is administered in accord with 
authorized use.  However, if the infant experiences an SAE associated with such a drug, the 
SAE is reported together with the exposure during breastfeeding.
[IP_ADDRESS]. Occupational Exposur e
An occupational exposure occurs when a person receives 
unplanned direct contact [CONTACT_22839] , which may  or may  not lead to the occurrence of an AE. Such persons 
may include healthcare provider s, family members, and other roles that are invol ved in the 
trial participant’s care.
The inve stigator must report occupational exposure to[COMPANY_007] Safet y within 24 hours of the 
investigator’s awarenes s regardless of whether there is an associated SAE.
  The inf ormation 
must be reported using the CT SAE Report Form.  Since the information does not pe rtain to a 
participant enrolled in the study ,the information is not recorded on a CRF; however, a copy  
ofthe completed CT SAE Report Form is maintained in the inves tigator site file .
8.3.6. Cardiovascular and Deat h Events
Not applicable .
8.3.7. Disease -Related Events and/or Disease -Related Outcomes Not Qualifying as AEs 
or SAEs
Not applicable .
8.3.8. Adverse Events of Special Interest
Not applicable .
[IP_ADDRESS]. Lack of Efficacy
This section is not applica ble because efficacy  is not expecte d in the study population.

PF-[ADDRESS_118954] SAE Report 
Form to [COMPANY_007] Safe ty Within
24Hours of Awareness
Medication errors All (regardless of whether 
associated with an A E)Only  if associated with an SAE
Medicat ion errors include:
Medication errors involving participant exposure to the study  intervention ;
Potential medicatio n errors 
or uses outside of what is foreseen in the protocol that do 
or do not involve the study participant .
Such medication errors occurrin g toa stud y participant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE page.
Inthe event of a medication dosing e rror,the sponsor should be notified within 24 hours .
Whether or not the medication error is accompanied by  [CONTACT_1149], as determined by  [CONTACT_1275], the medication error is r ecorded on the medication erro r page of the CR F and, if 
applicable, an y associate d AE(s), serious and nonserious, are recorded on theAE page of the 
CRF.
Medication error s sh
ould be reported to [COMPANY_007] Safety  within [ADDRESS_118955] SAE Report 
Form only w hen associated with an SAE.
8.4.Treatment of Overdose
For this study , any  dose of PF-06882961 greater than 300mgwithin a 24- hour tim e 
period ±
2hours will be considered an ov erdoseas this was the highest dose administered in 
the C3421001 study .
Sponsor does not recommend specific treatme nt for an overdo se.

PF-[ADDRESS_118956] ose, th e investigator/treating ph ysician should:
1.Contac t the medical m onitor within 24 hours .
2.Closely monitor the participant for an y AEs/SAE sand laboratory  abnormalities for at 
least 5 half -lives or 28 calendar day s after the overdose of PF-06882961 (whichever 
is longer).
3.Document the quant ityof the excess dose as well as the duration o f the over dose in 
the CRF.
4.Overdose is reporta ble to Safety  only when associated with a nSAE.
5.Obtain a blood sample for PK anal ysis within 2days from the da te o
f the last d ose of 
study  intervention if requested by [CONTACT_7195] (determined on a case -by-case 
basis). 
Decisions regarding dos e interruptions or modifications will be made by [CONTACT_107089] m onitor based on theclinical evaluation of the participant.
8.5.Pharma cokinetics 
8.5.1. Plasm a for Analysis of PF -[ADDRESS_118957] es of approximately  3mL, to provide a minimum volume of 1 mL plasma, will 
be collected into appropriately  labeled tubes containing dipotass
ium 
ethylenediam inetetr aacetic acid (K 2EDTA) for measureme nt of plasma conc entrations of 
PF-[ADDRESS_118958] nominal time relative to dosing.  Collection of 
samples up to and including 10 hour s after dose administration that are obtained withi n 
10% of the nomi nal time relative to dosing (eg, within 6 minutes of a 60 -minute sample) will
not be captured as a protocol deviation, as long as the exact time of the collection is noted on 
the source do cume nt and theCRF.  Collection of samples more tha n 10 hours after dose
administration that are obtained ≤
1hour away  from the nominal time relative to dosing will 
not be captured as a protocol deviation, as long as the exact time of the collection is noted on 
the source document and theCRF. This protocol deviation window do es not apply  to 
samples to be col lected more than 10 hours after dose administration at outpatient/follow-up 
visits with visit windows.
Samples will be used to evaluate the PK of PF-06882961 . Samples collected for anal yses of 
plasma concentration may  also be used to evaluate safet y or ef ficacy  aspects related to 
concerns arising during or after the study , for metabolite identification and/or evaluation of 
the bioanal ytical method, or for other internal exploratory  purposes.

PF-[ADDRESS_118959] be processed and shipped as indicated in the instructions provided to 
the investigator site to maintain sample integrity .Any deviations from the PK sample
handling procedure (eg, sample c
ollection and processing steps, interim storage or shippi[INVESTIGATOR_15889]), including any actions taken, must be documented and reported to the sponsor.  
On a case -by-case basis, the sponsor may  make a determination as to whet her sample 
integrit y has been c ompromised.
8.5.2. Plasma for Determination of PF -06882961 Unbound Fraction Protein Binding 
During the study , a blood sample ( approximately  12 mL , to provide approximately  5mLof 
plasma) to provide sufficient plasma for unbound fr action determination , will be collected 
into an appropriatel y labeled tubes containing K2EDTA for measurement of plasma 
concentrations of PF-06882961 as specified in the SoA. Instructions for the collection and 
handl ing of biologi cal samples will be provided in the laboratory  manual or by  [CONTACT_456]. 
The actual date and time (24-hour clock time) of each sample will be recorded.
The actual times may  change, but the number of samples will remain the same.  All efforts 
will be made to obtain the samples at the exac t nominal time relative to dosing.  Collection of 
samples up to and including 10 hours after dose administration that ar eobtained within 
10% of the nominal time relative to dosing (eg, within [ADDRESS_118960] e)will 
not be captured as a prot ocol deviation, as long as the exact time of the collection is noted on 
the source document and theCRF.  Collection of samples more than 10 hours after dose
administration that are obtained ≤
1hour away  from the nominal time relative to dosing will 
not be captured as a protocol deviation, as long as the exact time of the collection is noted on 
the source document and theCRF. This protocol deviation window does not apply  to 
samples to be col lected more than 10 hours after dose administration at outpatient/follow -up 
visits with visit windows.
Samples collected for analy ses of PF -06882961 binding may also be used to evaluate safet y 
or efficacy  aspects related to concerns arising during or after the study , for metabolite 
identification and/or evaluation of the bioanal ytical method, or for other internal exploratory  
purposes.
Genetic anal yses will not be performed on these plas ma samples unless consent for this was 
included in the informed consent
.  Participant confidentiality  will be maintained.
Samples collected for measurement of plasma concentrations of study  intervention/other will 
be anal yzed using a validated anal ytical m ethod in compliance with applicable SOPs.  
Potential metabolites may  beanalyzed with either validated or exploratory  methods.

PF-[ADDRESS_118961] be processed and shipped as indicated in the instructions 
provided to the investigator site to m aintain sample integrity .  An y deviations from the 
Protein Binding samp le handling procedure (eg, sample collection and processing steps, 
interim storage or shippi[INVESTIGATOR_19944]), including any  actions taken, must be documented and 
reported to the sponsor. On a case -by-case basis, the sponsor may  make a determination as 
to whether sample integrity  has been compromised.
8.6.Pharmacodynamics
Pharmacod ynamic parameters are not evaluated in this study .
8.7.Genetics
8.7.1. Specified Genetics
Genetics (specified analyses) are not evaluated in this study .
8.7.2. Banked Biospecimens for Genetics
A 2mL blood sample optimized for DNA isolation 
(Prep D1.5) will be collected as local 
regulations and IRBs/ECs allow.
Banked Biospecimens may be used for research related to thestudy  intervention (s).  Genes 
and other analy tes (eg ,proteins, RNA, nondrug metabolit es) may  be studied using the banked 
samples. 
See Appendix 5for information regarding genetic research.  Details on processes for 
collect ion and shipment of these samples can be found in supporting documentation.
8.8.Biomarker s
Biomarkers are not evaluated in this study .
8.9. I mmunogenicity Assessments
Immunogenicit y assessments are not included in this study .
8.10. Health Economics
Health e conomics/ medical resource utilization and health e conomics parameters are not 
evaluated in this stu dy.
9.STATISTICAL CONSIDER
ATIONS
Detailed methodology  for summary  and statistical anal yses of the data co llected in this study  
is outlined here and further detailed in a statistical anal ysis plan ( SAP), which will be 
maintained b y the sponsor.  The SAP may m odify  what is outlined in the protocol where 
appropriate; however, any  major modifications of the prima ry endpoint definitions or their 
analyses will also be ref lected in a protocol amendment.

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page 549.1.Statistical Hypotheses
No formal s tatistical hy pothesis testing will be performed in this study .
9.2.Sample Size Determination
A sample size of approximately  24 participants (approximately  6 participants per cohort, 
with vary ing degrees of hepatic function in each of the 4 cohorts) has been se lected to 
provide sufficient precision to detect a 2- fold difference in AUC infbetween each Test cohort 
(with hepatic impairment) and the Reference cohort (without hepatic impairment). Table 2
presents the 90% CIs (with 80% coverage probability ) for various p ossible effects on AUC inf.
The same table would be applicable for possible effects on C max.
Table 2. Expected Widths of the 90% CIs (with 80% Coverage Probability) for 
Different Possible Estimated Effects
Estimated Effect
(Test/Refe rence)AUC inf
Probable 90% CI Probable CI Width
75% 43% to 129% 86%
100% 58% to 172% 114%
150% 87% to 259% 172%
200% 116% to 345% 229%
400% 232% to 690% 458%
These estimates are based on an assumed conservat ive between- participant standard 
deviatio n of 0.489 (equivalent to a geometric coefficient of variation of 52%) for log eAUC inf
(also applicable to log eCmax) based on data from 2 previous studies conducted in health y 
volunteers with PF
-06882961 administered as a single dose in the fed state (C3421 001 & 
C3421003) .
Participants who discontinue from the stud y before completing all assessments may  be 
replaced at the discretion of the investigator and sponsor.
9.3.Analysis Sets
For purposes of analy sis, th e following 
analysis sets are d efined:
Participant A nalysis 
SetDescription
Enrolled "Enrolled" means a participant's agreement to participate in a 
clinical study  following completion of the informed consent 
process. 
Evaluable All participants assigned to I P and who take at least 1dose of IP.
Safety All participants assigned to IP and who take at least 1dose of IP.

PF-[ADDRESS_118962] calculated.
9.4.Statistical Analyses
The SAP will be developed and fina lized before any  anal yses are pe rformed and will 
describe the anal yses and procedures for accounting for missing, unused, and spurious data. 
This section is a summary of the planned statistical analy ses of the pr imary ,secondary and 
selected tertiary /exploratory endpoints.
9.4.1. Pharmacokinetic Analyses
[IP_ADDRESS]. Derivation of Pharmacokinetic Parameters
The plasma PK parameters for PF -[ADDRESS_118963] ing 
times will be used in the derivation of PK parameters. In the case that actual PK sampling 
times are not available, nominal PK sampling tim
e will be used in the derivation of PK 
parameters. The fraction of PF -06882961 unbound in plasma (fu) will be d etermined and 
reported for each participant by [CONTACT_107090].

PF-[ADDRESS_118964] 
quantifiable concentration (C last).Linear/Log trapezoidal method.
AUC inf* Area under the plasma 
concentration -time profile from
time zero extrapolated to infinite 
time.AUC last+ (C last*/k el), where C last*
is the predicted plasma 
concentration at the last 
quantifiable time point estimated 
from the log -linear regression 
analysis.
Cmax Maximum plasma concentration. Observed directl y from data.
Tmax Time for C max. Observed directly from data as 
time of first occurrence.
t1/2* Term inal half -life. Loge(2)/k el,
where k elis the terminal phase 
rate constant calculated by a linear 
regression of the log -linear 
concentration -time curve. O nly 
those data points judged to 
describe the terminal log -linear 
decline will b e used in the 
regression.
CL/F* Apparent clearance. Dose/AUC inf.
Vz/F* Apparent volume of distribution. Dose/(AUC inf*kel). 
fu Fraction of unbound drug in 
plasmaCu/C (where Cu represents 
unbound concentration and 
Crepresents total concentration) .
AUC last,u Unbound A UC 0-last fu*AUC last.
AUC inf,u Unbound AUC 0-inf fu*AUC inf.
Cmax,u Unbound C max fu*C max.
CL u/F Unbound CL/F Dose/(AUC inf,u).
Vz,u/F Unbound V z/F Dose/(AUC inf,u*kel).
* as data perm it
[IP_ADDRESS]. Statistical Methods for Pharmacokinetic Data
The effe ct of vary ing de grees of hepatic impairme nt on PK parameters will be assessed b y 
constructing 90% CIs around the estimated difference between each of the Test (hepatic 
impaired) cohorts and the Reference (without hepatic impairment) cohort. A 1-way analysis 
of variance ( ANOVA) will be used to co mpare the natural log transformed PF -
[ADDRESS_118965], and fraction unbound (fu), as data permit, for each of the hepatic 
impairment cohorts (Test) to the cohort without hepatic impairment ( Reference). Estimates 
of the adjusted mean differen ces (Test - Reference), and corresponding 90% confidence 
intervals, will be obtained from the model. These will be exponentiated to prov ide estimates 
of the ratio of adjusted geometric means (Test/Refere nce) and 90 % confidence int ervals for 
the ratios.

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page 57Additional exploratory  analy sis using linear regression will be used to analyz e the potential 
relationship between appropriate PK pa rameters [eg, AUC inf, AUC last, Cmaxand fu] and 
hepatic function (e g, serum albumin c oncentration, pr othrombin time or total bilirubin).
Plots of PK parameters (eg, AUC inf, AUC last, Cmaxand fu) versus hepatic function will be 
constructed, with a regressi on line and 90% confidence region included. Estimates of the 
slope and intercept, to gether with a 90% CI, and the coefficient of determination (ie , R-
squared and adj -R-squared) will be obtained from the model.
Additionally , as a n exploratory analy sis, age and body  weight may  be explored as an 
additional covariate/factor in the models, as appropriate.
Individual PF -[ADDRESS_118966], Cmax, unbound AUC inf(AUC inf,u), unbound AUC last
(AUC last,u),and unbound C max(Cmax,u) individual 
participant parameters will be plotted by  
[CONTACT_107091]. PKparameters of PF -0688296 1 will be summarized descriptivel y 
by [CONTACT_107092]. Unbound fraction (fu) will be listed and summarized 
descriptivel y by [CONTACT_107092].
9.4.2. Safety Analyse s
All safet y anal yses will be performed on the s afety popul ation.
AEs, ECGs, BP, 
pulse rate , and safety  laboratory  data will be reviewed and summarized on 
an ongoing basis during the study  to evaluate the safet y of participant s.  Any  clinical 
laboratory , ECG, BP, and pulse rate abnormalities of pot ential clinical concern will be 
described .  Safet y data will be presented in tabular and/or graphical format and summarized 
descriptivel y, where appropriate.
Medical history  and phy sical examination and neurological examination information, as 
applicable, collected during the course of the study  will be considered source data and will 
not be required to be reported, unless otherwise noted.  However, an y untowa rd findings 
identified on phy sical and/or neurological e xaminations conducted during the active 
collection period w ill be captured as AEs, i f those findings meet the definition of an AE.  
Data collected at screening that are used for inclusion/exclusion criteria, such as laboratory  
data, ECGs, and vital signs, will be considered source data, and will n ot be required t o be 
reported, unless otherwise noted.  Demographic data collected at screening will be reported.   
COVID -
19 specific assessm ents data will be considered source data and will not be required 
to be reported.

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page [IP_ADDRESS]. Electrocardiogram Anal yses
Changes from baseline f or the ECG parameters QT interval, heart rate, QTcF interval, PR 
interval, and QRS complex will be summarize d by [CONTACT_107093].
The number (%) of 
participants with maxim um postdose QTc Fvalues and maximum 
increases from baseline in the following categories will be tabulated by  [CONTACT_107094] : 
Safety QTc FAssessment
Degree of Prolongation Mild(msec
) Moderate (msec) Severe (m sec)
Absolute value >450-480 >480-500 >500
Increase from baseline 30-60 >60
9.4.3. Other Analyse (s)
Pharmacogenomic or biomarker data from Banked Biospecimens may  be collected during or 
after the trial and r etained for future anal yses; the results of such analy ses are not planned to 
be include d in the CSR.
9.5.Interim Analyses
No formal int erim anal ysis will be conducted f or this study . As this is an open- label 
study ,the sponsor may  conduct unblinded reviews of the data during the course of the study  
for the purpose of safet y assessment, facili tating PK modeling, and/or support ingclinical
development. 
9.6.Data Monitoring Co mmittee or Other Independent Oversight Committee
This study  will not use a data monitoring c ommittee ( DMC ). 

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page 5910. SUPPORTING DOCUMENTA TION AND OPERATIONAL CONSIDERATIONS
10.1. Appendix 1: Re gulatory, Ethical, and Study Oversight Considerations
10.1.1. Regulatory and Ethical C onsiderations
This study  will be conducted in accordance with the protocol and with the fol lowing:
Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and CIOMS International Ethical Guidelines ;
Applica ble ICH GCP guidelines ;
Applicable laws and regulations , including applicable privacy  laws .
The protocol, pr otocol amendments, I CD, SRSD(s) , and other relevant documents 
(eg,advertisements) must be 
reviewed and approved by  [CONTACT_107095]/EC by  [CONTACT_107096]/EC before the study  is 
initiated.
Any amendm ents to the protocol will require IRB/EC approval before implementa tionof 
changes made to the study design, except for changes necessary  to elimina te an immediate 
hazard to study  participants.
The investigator will be responsible for the f ollowing:
Provid ing written summaries of the status of the study  to the IRB/EC annuall yor 
more frequently  in accordance with the requirements, policies, and proced ures 
established by  [CONTACT_1201]/EC ;
Notify ing the IRB/EC of SAEs or other significant safet y findings as require d by 
[CONTACT_1744]/EC procedures;
Providing oversight of the conduct of the s tudyat the site and adherence to 
requirements of 21 CFR, ICH guidelines, the IRB/EC, European regulation 536/2014 
for clinical studies (if applicable), and all other applic able local regulations.
[IP_ADDRESS]. Reporting of Safe ty Issues and Serious Breaches of the Prot ocolor ICH GCP
In the event of an y prohibition or restriction imposed (ie, clini cal hold) b y an applicable 
regulatory  authorit y in any area of the world, or if the investig ator is aware of any new 
information that might influence the evaluation of the ben efits and risks of the study  
intervention , [COMPANY_007] should be informed immediately .
In addition, the investigator will inform [COMPANY_007] immediately  of any  urgent safet y measure s 
taken b y the i nvestigator to protect th e study  participants against an y immediate ha zard, and 
of an y serious breaches of this protocol or of ICH GCP that the inves tigator becomes aware 
of.

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page 6010.1.2. Financial Disclosure
Investigators and subinvestigators will prov ide the sponsor with sufficient , accurate financial 
information as requested to allow t he sponsor to submit complete and accurate financial 
certification or disclos ure statements to the appropriate regulatory  authorities. Investigators 
are responsible for providing infor mation on finan
cial inter ests during the course of the stud y 
and for 1 year after completion of the study .
10.1.3. Informed Consent Process
The investigator or his/her representative will explain the nature of the study  to the 
participant and answe r all questions regarding the s tudy.  The participan tshould be given 
sufficient time and opportunity  to ask questions and to decide whether or not to participate i
n
the trial.
Participants must be informed that their participation is voluntary . Participa ntswill be 
required to sign a statement of informed consent that meets the requiremen ts of 21 CFR 50, 
local regulations, ICH guidelines, HI PAA requirements, where applicable, and the IRB/EC 
or study  center.
The investigator must ensure that each study  participant is full y informed abou t the natu re 
and objectives of the study, the sharing o fdata related to the study ,and possible risks 
associated with participation, including the risks associated with the processing of the 
participant ’s personal data. 
Theparticipant must be informed t hat his/he r personal study -related data will be used by [CONTACT_20004]. The level of discl osure must also be 
explained to the participant.
The participant must be informed that his/h er medical recor ds may  be exami ned by  [CONTACT_107097], by  
[CONTACT_6667]/EC members, and by [CONTACT_90742].
The investigator further must ensure that each s tudy participant is fully  infor med about his or 
her right to access and correct his or her personal data and to withdraw consent for the 
processing of his or her pe rsonal data.
The medical record must include a statement that written informed consent was o btained 
before t he participant was enroll ed in the study
 and the date the written conse nt was obtained.
The authorized person obtaining the informed consent must also sign the ICD.
Participants must be reconsented to the most current version of the IC D(s) during their 
participation in the study .
A cop y of the IC D(s) must be provided to the participan t.
Participants who are rescreened are required to sign a new IC D.

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page 61Unless prohibited by  [CONTACT_20006]/EC decision, the ICD will contain a separate
section that addresses the use of sample s for optional additional research.  The opti onal 
additional research does not require the collection of an y further sample s.  The investigator 
or authorized designee will explain to each participant the objectives of the additio nal 
research.  Participants will be told that they  are free to refuse to participate and may  
withdraw their consent at any  time and for any  reason dur ing the storage period.  A separate 
signature [CONTACT_22862] a participant's a greement to al low specimens to be 
used fo r additional research.  Participants who decl i
ne to participate in this optional 
additional research will not provide this separate signature.
10.1.4. Data Protection
All parties will comply  with all applicable laws, includ ing laws regar ding the implementation 
of organizational and technical measures to ensu re protection of participant data.
Participants’ personal data will be stored at the study  site in encry pted electronic and/or paper 
form and will be password protected o r secured in a locked room to ensure that only 
authorized study  staff have access.  The study  site will implement appropriate technical and 
organizational measures to ensure that the personal data can be recovered in the event of 
disaster.  In the event of a potential p ersonal data breach, the st udy site will be responsible 
for determining whether a personal data breach has in fact occurred and, if so, providing 
breach notifications as required by  [CONTACT_2371].
To protect the rights and freedoms of participants with regard to the processing of personal 
data, participants will be assigned a single, 
participant -specific numerical code. Any 
participant records or data sets that are transferred to the sponsor will contain the numerical 
code; participant names will not b e transferred. All other identifiable da ta transferred to the 
sponsor will be identif
ied by  [CONTACT_20007], participant- specific code. The study  site will 
maintain a confidential list of participant s who participated in the study, linking each 
participant ’snumerical cod e to his or her actual iden tityand medical record identification . In 
case of data transfer, the sponsor will protect the confidentiality  of particip ants’ personal data 
consistent with the c linical study agreement and applicable privacy  laws .
10.1.5. Dissemination of Clinical Study Data
[COMPANY_007] fulfills its commitment to publicly  disclose clinical study  results through posting the 
results of studies on www.clini caltrials.gov (ClinicalTrials.gov), the EudraCT, and/or 
www.pfizer.com, and other public re gistries in accordance with applicable lo cal 
laws/regulations.  In addition, [COMPANY_007] re ports study  results outside of the requirements of local 
laws/regulations purs
uant to its SOPs.
In all cases, stud y results are reported b y [COMPANY_007] in an objective, accura te, balanced, an d 
complete manner and are reported regardless of the outcome of the study  or the country  in 
which the study  was conducted.

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page 62www.clinicaltrials.gov
[COMPANY_007] posts clinical trial results on www.clinicaltrials.gov for [COMPANY_007]- sponsored interventio nal 
studies (conducted in patients) that evaluate the safety  and/or efficacy  of a prod uct, 
regardless of the geographical location in which the study  is conducted. These r esults are 
submitted for posting 
in accordance with the format and timelines set for thby [CONTACT_20008].
EudraCT
[COMPANY_007] posts clinic al trial r esults on EudraCT for [COMPANY_007] -sponsor ed interventional studies in 
accordance with the format and timelines set for th by [CONTACT_20009].
www.pfizer.com
[COMPANY_007] posts public disclosure s ynopses (CSR synopses inwhich an y dat a that could be used 
to identify  individual participants have been rem oved) on www.pfizer.com for 
[COMPANY_007] -sponsored interventional studies at the sam etime the corresponding study  results are
posted to www.clinicaltrials.gov .
Documents withi n marketing auth orization packages/submis sions
[COMPANY_007] complies with the European Union Policy  0070, the proactive publication of clinical 
data to the EMA website.   Clinical data, under Phase 1 of this policy ,includes clinical 
overviews, clinical summaries , CSRs, and appe ndices containing the protocol and protocol 
amendments, sample CRF s, 
and statistical methods. Clinical data, under Phase 2 of this 
policy ,includes the publishing of individual participant data. Policy  0070 applies to new 
marketing author ization applications submitted via the ce ntrali zed procedure since 
01January 2015 and applications for line extensions and for new indications submitted via 
the ce ntralized procedure since 01 July  2015.
Data Sharing
[COMPANY_007] provides researchers secure acce ss to patient -level data or full CSRs for the purposes 
of “bona -fide scientific resear ch” that contribute sto the scientific understanding of the 
disease, target, or compound class. [COMPANY_007] will make available data from these trials 
24months after study  completion.  Pati ent-level data will be an onymized in accordance with 
applicable privac ylaws and regulations. CSRs will have personall y identifiable information 
redacted.
Data requests are considered from qualified researchers with the appropriate compete ncies to 
perform the proposed analy ses. Research teams must include a biostatistician. Data will not 
be provided to applicants with significant conflicts of inter est, including individuals 
requesting access for commercial/competitive or legal purposes.

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page 6310.1.6. Dat a Quality Assu rance
All participant dat a relating to the stud y will be recorded on pr inted or electronic CRF unless 
transmitted to the sponsor or designee electron ically  (eg, laboratory  data). The investigator is 
responsible for verify ing that data entr ies are accurate and correct by  [CONTACT_55896] y or 
electronically  signing the CRF.
The inves tigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.
The investigator must ensure that the CRFs are securel y stored at the study site in encry pted 
electro nic and/or paper form and are passwor d protecte d or secured in a locked room to 
prevent access b y unauthorized third partie s.
The investigator must permit study -related monitoring, audits, IRB/EC review, and 
regulat ory agency  inspe ctions and provide direct access to source data documents.   This 
verifi cation may  also occur after study  completion.  I t is important that the inves tigator(s) 
and their relevant personnel are available during the monitoring visits and possi ble audits or 
inspections and that suffic ient time is devoted to the process.
Monitorin gdetails describing strategy  (eg, risk
-based initiatives in operations and q uality  
such as risk management and mitigation strategies and analytical 
risk-based monitoring), 
methods, res ponsibilities, and requir ements, including handling of noncomp liance iss ues and 
monitoring techniques (central, remote, or on -site monitoring) ,are provided in the study  
monitoring 
plan (SMP) .
The sponsor or designee is responsible for the data management of this study ,including 
quality  checking of the data.
Study  monitors w ill perform ongoing source data verification to confirm that data entered 
intothe CRF by  [CONTACT_1191], complete, and verifiable from source 
documents; that the safety and rights of pa rticipants are being protected; and t hat the s tudy is 
being conducted in accordance with the currently
 approved protocol and any other study  
agreements, I CH GCP, and all applicable regulatory  requirements.
Records a nd documents, including signed IC Ds, pertaining to the conduct of this study  must 
be re tained b y the investigator for 15years after study  completion unless local r egulations or 
institutional policies require a longer retention period. No records may  be d estroy ed during 
the retention period with out the written approval of the spons or.No records may  be 
transferred to another location or part y without written notification to the sponsor. The 
investigator must ensure that the records continue to be stored securel y for aslong as they  are 
maintain ed.
When participant data are to be deleted, t he investigator will ensure that all copi[INVESTIGATOR_107066] y deleted from all systems.

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page 64The investigator(s) will notify  the sponsor or its agents immediately  of any regulatory  
inspection notification in rel ation to the study .  Furth ermore, the investigator will cooperate 
with the sponsor or its agents to pre pare the investigator site for the inspection and will allow 
the 
sponsor or its agent, whene ver feasible, to be present during the in spection.  The 
inves tigator site and investigat or will promptly  resolve any  discrepancies that are identified 
between the s tudy data and the participant's medical records.  The investigator will promptly  
provide copi[INVESTIGATOR_107067].  Before response 
submission to the regulatory  authorities, the investigator will provide the sponsor or its 
agents with an opportunity to review and comment on responses to an y such findings.
10.1.7. Sour ce Documents
Source documents provide evi dence for the existe nce of the participant and substantiate the 
integrit y of the data collected.   Source documents are file dat the investigator site.
Data reported on the CRF or entered in the eCRF that are from so urce documents m ust be 
consistent with th e source documents o
r the discrepancies must be explained . The 
investigator may  need to request previous medical records o r transfer records, depending on 
the study . Also, current medical records must be available .
Definition of what constitutes source d ata can be found in the SMP .
Description of theuse of computerized sy stem is documented in the Data Management Plan
(DMP) .
10.1.8. Study and Site Start and Closure
The study  start date is the date on which the clinical study  will be open for recruitment of 
participants.
The first act of recruitment is the d
ate of the first participant’s first visit and will be the study  
start date.
The sponsor designee reserves the right to close the study  site or terminate the study at an y 
time for an y reason at the sole di scret ion of the sponsor. Study  sites will be closed upon 
study  completion. A study  site is considered closed when all required documents and study  
supplies have been collected and a stud y-site closure visit has been pe rformed.
The investigator may  initia te study-site closure at any  time upon notification to the sponsor 
or designee/ CRO if requested to do so by  [CONTACT_51025] I RB/EC or if such termination is 
required to protect the health of study  participants .
Reasons f or the earl y clo sure of a stud y site by [CONTACT_95500]:
Failure of the investigator to comply  with the protocol, the requirements of the 
IRB/EC or local health authorities, the sponsor's procedures, or GCP guidelines;

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page 65Inadeq uate recruitment of participants by  [CONTACT_941] i nvestigator ;
Discontinuation of further study  intervention development .
If the stud y is prematurely terminated or suspended ,the sponsor shall promptly  inform the 
investigators, the ECs/IRBs, the regulatory  authorit ies, and an y CRO (s) used in the stud y of 
the reason for termination or suspension, as s
pecified by  [CONTACT_20013]. The investigator shall p romptly  inform the participant and should assure 
appropriate 
participant therapy  and/or foll ow-up.
Study  termination is also provided for in the clinical study  agreement.  If ther eis an y conflict 
between the contract and this protocol, the contract will c ontrol as to termination rights.
10.1.9. Publication Policy
The results of this study  may  be publish ed or presented at scientific meetings b ythe 
investigator after publication of the ove
rall study  results or 1year after the end of the stud y 
(or study termination ), whichever comes first. 
The investigator agrees t o refer to the primary  publication in an y subsequent publications 
such as seconda ry manuscripts, and submit s all manuscripts or abstracts to the sponsor 
30days before submission. This allows the sponsor to protect proprietary  information and to 
provide c omments and the investigator will, on re quest, remove an y previously  undisclosed 
confidential information before disclosure, ex cept for an y stud y-or [COMPANY_007] -intervention 
related information necessary  for the appropriate scientific presentation or understan ding of 
the study  results.
For all publi cations relating to the study , the invest igator will compl y with recognized ethical 
standards concerning publications and authorship, including those established by [CONTACT_107098].
The sponsor will comply  with the re
quirements for p ublication of the over allstudy  results 
covering all i nvestigator sites .  In accordance with standard editorial and ethical practice, the 
sponsor wi ll support publication of multicenter studies only  i
n their entirety and not as 
individual site data.   In this case, a coordinating i nvestigator will be designated b y mutual 
agree ment.
Authorship of publications for the overall study  results will be determi ned by  [CONTACT_78275] I nternatio nal Committee of Medical Journal Editors authorship 
requirements. 
If publication is addressed in the clinical study  agreement, the publication policy  set out in 
this section will not apply.

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page 6610.1.10. Sponsor’s Qual ified Medical Personnel
The contact [CONTACT_1133]'s appropriately  qualified m edical personnel for the 
study  is documented in the study  contact [CONTACT_22848] (SToD).
To facilitate access to appropriatel y qualified m edical personnel on study -related medical 
questions or problems, participant s are provided w ith a contact [CONTACT_107099] d 
consent .  The contact [CONTACT_4662], at a minimum, protocol and study  intervention
identifiers, participant numbers, cont a
ct information for the investigator site, and contact 
[CONTACT_4664] a contact [CONTACT_107100] e
vent that the in vestigator site staff cannot be reached to 
provide advice on a medical question or problem originating from another healthcare 
professional not invo lved in the 
participant ’s participation in the study .  The contact [CONTACT_107101] b y investigator s taff if they  are seeking advice on medical questions or 
problems; howev er, it should be used only  in the event that the established communication 
pathway s between the investi gator site and the study  team are not available.  I t is therefore 
intended to augm ent, but not replace, the established communication pathway s between th e
investigator site and the study  team for advice on medical questions or problems that may  
arise durin g the stud y.  For sites other than a [COMPANY_007] CRU, the contact [CONTACT_107102] r is not intende d 
for use b y the particip antdirectly , and if a 
participant calls that number, he or she will be 
directed back to the investigator site.

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page 6710.2. Appendix 2: Clinical Laboratory Test s
The following safet y laboratory  tests will be performed at times defined in the SoA section of 
this protocol.  Additional labor atory results may be reported on these samples as a result of 
the method of an alysis or the ty pe of anal yzer used by  [CONTACT_20019] ,or as derived 
from calculate d values.  These additional tests would not require additional collection of 
blood.  U nscheduled clinical laboratory  measurements may  be obtained at any  time during
the study  to assess any  perceived safety  issues.
Table 4. Protocol -Required Safety Laboratory Assessments
Hematology Chemistry Urinalysis Other
Hemoglobin
Hematocrit
RBC count
Reticulocyte count (Abs)
MCV
MCH
MCHC
Platelet count
WBC count
Total neutrophils (Abs)
Eosinophils (Abs)
Monocytes (Abs)
Basophils (Abs)
Lymphocyt es (Abs)BUN
Creatinine
eGFR eGFR)
Gluco se (fasting)
Calcium
Sodium
Potassium
Chloride
Phosphorus
Total CO 2(Bicarbonate)
AST
ALT
Alkaline phosphatase
GGT
Total bi lirubin
Direct bilir ubina,b
Indirect bilirubina,b
Creatine kinasea,c
Uric acid
Albumin
Total protein
Amylase
LipasepH
Glucose (qual)
Protein (qual)
Blood (qual)
Ketones
Nitrites
Leukocyte esterase
Urobilinogen
Urine bilirubin
MicroscopydOther tests as p art of clinical 
laboratory tests: 
 aPTT, PT, PT control, INR
 Serum FSHe
 Serumfand urinegpregnancy 
test
 Breath alcohol testg
 Urine d rug testh
 Serologyi: HBsAg, HCVAb
(and if positive, reflex HCV 
RNA) , and HIV
 HbA1c
 COVID -19 testj
Additional Tests (Needed for Hy’s law )
AST 
ALT 
Total bilirubin
Albumin 
Alkaline phosphatase 
Direct bilirubinIndirect bilirubi n
Creatine kinase
GGT
PT/INR
Total bile a cids
Acetaminophen drug levels and/or protein adduct level
a. At screening and Day 1, only.
b. After Day 1, direc tand indirect bilirubin assessed when total bi lirubin is > ULN , only .
c. After Day 1, creatine kinase assesse dwhen ALT is > ULN, only.
d. Only if urine dipstick is positive for blood, protein, nitrites, or l eukocyte esterase.
e. To be assessed in allfemales (at screening only).
f. Serum testing in allfemales at all times when safety -related laboratory assessments are p erformed; urine testing to
be done on -site using kits provided by [CONTACT_3211]-identified central laboratory, in WOCBP, only.
g. Testing to be performed on-si te, at screening and Day -1, only using kits provided by [CONTACT_3211] -identified central
laboratory .
h. For urine drug test, minimum requirements include c ocaine, tetrahydrocannabinol (THC), opi[INVESTIGATOR_858]/opi[INVESTIGATOR_2438], 
benzodiazepi[INVESTIGATOR_103856].
i. At screening, only.
j. May be conducted at central o rlocal labo ratory .
For list of abb reviations, refer to Section 10.[ADDRESS_118967] document their review of each laboratory  safet y report.

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page 6810.3. Appendix 3: Advers e Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
10.3.1. Definition of AE
AE D efinition
An AE is an y untoward medical occurr ence in a patien t or clinical study  
participant, temporall y associated with the use of study interv ention, whether or not 
considered relate dto the study  intervention.
NOTE: An AE can therefore be an y unfavora ble and uni ntended sign (including an 
abnormal 
laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of study  intervention.
Events Meeting theAE Definition
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) 
or other safet y assessments (eg , ECG, radiological scans, vital sign measurements), 
including those that worsen fr om baseline, considered clinicall y signi ficant in the 
medical and scientific judgment of the investigator. Any abnormal laboratory test 
results that meet an y of the conditi ons below must be recorded as an AE:
Is associated with accompany ing s ymptoms
;
Requires additional diagnostic testing or me dical/surgical intervention;
Leads to a change in study  dosing (out side of an y protocol -specified dose 
adjustments) o r discontinuatio n from the study , significant additional 
concomitant drug treatment, or other thera p
y.
Exacerbation of a chronic or intermi ttent preexisting condition including either an 
increase in frequen cy and/or intensity  of the condition.
New conditions detected or diagnosed after stud y intervention administration even 
though it may  have been prese nt before the start of the study .
Signs, symptoms, or the clinical sequelae of a suspected drug -drug intera ction.
Signs, sy mptoms, or the clinical sequelae o f a suspected ov erdose of either study  
intervention or a concomitant medication. Overdose per se w i
llnot be reported as 
an AE/SAE unless it is an intentional overdose taken with possible 
suicidal/self- harming intent. Such overdoses should be reported re gardless of 
sequelae.

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page 69Events NOT Meeting the AE Definition
Any clinically  significant abnormal l aboratory  findings or other abnormal saf ety 
assessments which are associated with the underl ying disease, unle ss judged by  [CONTACT_107103] f or the participant’s condition.
The disease/disorder being studied or expected prog
ression, signs, or s ymptoms of 
the disea se/disorder being studied, unless more severe than expect ed for the 
participant’s condition.
Medical or surgical proc edure (eg, endos copy , appendectom y): the condition that 
leads to the procedure is the AE.
Situation s inwhich an untoward medical occurrenc edid not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of preexisti ngdisease(s) or condition(s) present 
or detected at the start of the study that do not worsen.
10.3.2. Definition of SAE
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
condit ions are met (eg, hospi[INVESTIGATOR_1080]/sym ptoms of the dis ease under study , death 
due to progression of disease).
AnSAE is defined as any un towa rd medical occurrence that, at any d ose:
a.Results in death
b.Is life -threatening
The term “life-threatening ”in the definition of “serious” refers to an e vent in which th e 
participant was at risk of death at the time of the event. It does not refer to an event that
hypothetically  might have caused death if it were more severe.
c.Requir es inpatient hospi[INVESTIGATOR_107068], hosp italization signifies that the participant has been detained (usually  
involving at least an overnight stay ) at the hospi[INVESTIGATOR_19950]/or tr eatment that would not have been appropriate in the ph ysician’s office or
outpatient sett ing. Complications that occur during hospi[INVESTIGATOR_1084]. If a 
complication p
rolongs hospi[INVESTIGATOR_9236], the event is 
serious .When in doubt as to whe ther “hospi[INVESTIGATOR_059]” occurred or was necessar y,the AE 
should be considered serious.

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page 70Hospi[INVESTIGATOR_5187] a preexisting con dition that did not worsen from 
baseline is not considered an AE.
d.Results in persis tent disability/incapacity
The term disability means a substantial disruption of a person ’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor med ical 
significance such as uncomplicated head ache, nausea, vomiting, di arrhea, 
influenza, and accidental trauma (eg, s prained ankle) w hich may  interfere with or 
prevent every day life functions but do not constitute a s
ubstantial disruption.
e.Is a congenital anomaly/birth defect
f.Other situations:
Medical or scientific judgmen t should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that 
may not be immediatel y life-threatening or result in death or hospi[INVESTIGATOR_107069] o utcomes listed in the above definition. These events 
should usually  be considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment 
in an emergency  room or at home for allergic bronchospasm, blood dyscrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug 
dependency  or drug abuse.
Suspected transmission via a [COMPANY_007] product of an infecti ous agent, pathogenic or 
non-pathogeni c, is considered serious.  The event may  be sus pected from clin ical 
symptoms or laboratory  findings indicating an infection in a patient exposed to a
[COMPANY_007] product.  The terms “suspecte dtransmission” and “transmissio n” are 
considered s ynon ymous.  These c ases are considered unexpected and handled as 
serious expedited cases by [CONTACT_20020].  Such cases are also 
considered for reportin g asproduct defects, if appropriate.
10.3.3. Re cording/Reporting and Follow -up of AE sand/or SAE s
AE and SAE Recordi ng/Reporting
The table below summarizes the re quirements for recording adverse events on the CRF and 
for reporting serious adverse events on the CT S AE Report Form to [COMPANY_007] Safety .  These 
requirements are delineated for 3 t ypes of events: (1) SAEs; (2) nonserious AEs; and 
(3)exposure to the study  intervention under study  during pregnancy  or breastfeeding, and 

PF-[ADDRESS_118968] SAE 
Repor t Form to [COMPANY_007] 
Safety Within 24 Hours of 
Awareness
SAE All All
Nonserious AE All None
Exposure to the study  
interventi onunder stud y 
during pregnancy  or 
breastfeeding, and 
occupational exp osureAll AEs/SAEs associated 
with exposure dur ing 
pregnancy  orbreastfeeding
Occupational exposure is 
not recorded.All (a
nd EDP supplemental 
for
m for EDP)  
Note: I nclude all SAEs 
associated with exposure 
during pregnancy  or 
breastfeeding. Include all 
AEs/SAEs associated with 
occupational exposure.
When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation ( eg,hospi[INVESTIGATOR_1088], laboratory  reports, and diagnostic 
reports) related to the event.
The investigato r will then record all relevant AE/SAE informatio n in the CRF.
It is notacceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s 
m
edical records to [COMPANY_007] Safety  in lieu of completion of the CT SAE Report 
Form /AE/SAE CRF page.
There may  beinstances when copi[INVESTIGATOR_21360] c ertain cases are
requested b y [COMPANY_007] Safety .In this case, all participant identifiers, with the 
exception of the participant number, will be redacted on the copi[INVESTIGATOR_19953] .
The investigator will attempt t o establish a di agnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not 
theindividual signs/sy mptoms) will be documented as the AE/SAE.

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page 72Assess ment of Intensity
The investigator will make a n assessment of intensity  for each AE and SAE reported 
during the stud y and assign it to 1 of the f ollowing categories: 
Mild: An event tha tis easily  tolerated by  [CONTACT_2299], causing minimal 
discomfort a nd not interfering with every day activities.
Moderate: An even tthat causes sufficient discomfort and interferes with normal 
every day activities.
S
evere: An event that prevents normal ev eryday activities. An AE that is assessed 
as severe should not be confused with a nSAE.   Severe is a category  utiliz edfor 
rating the intensit y of an event; and both AEs and SAEs can be assessed as severe.
An event is defined as “ serious” when it meets at least 1 of the predefined outcomes 
as described in the definition of an SAE, NOT when it is rated as severe.
Asses sment of Causali ty
The investigator is obligated to assess the relationship between stud y intervention
and each occurrence of each AE/SAE.
A “reasonable possibility” of a relationship conveys that there are f acts, evidence, 
and/or arguments to suggest a c ausal relationsh ip, rather than a relationship cannot 
be ruled out.
The investigator will use clini caljudgment to determine the relationsh ip.
Alternative causes, such as underl ying disease(s), concomitant the rapy, and other 
risk factors, as well as the te mporal relations hip of the event to stud y intervention 
administration, will be considered and inves tigated.
The investigator will also cons ult the IB and/or product information, for marketed 
products, in his/her ass essment.
For each AE/SAE, the investigato r must document in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assess ment of causality .
There may  be situatio ns in which an SAE has occurred and the investigator has 
minimal infor mation to include in the initial report to the sp onso r.Howeve r, it is 
very important that the investigator always make an assessment of causalit y
for every event before the initial tra nsmission of the SAE data to the sponsor .
The investigator may  change his/her opi[INVESTIGATOR_19954] -up 

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page 73information and send a nSAE follow -up report with the updated causality  
assessment.
The causali ty assessment is one of the criteria use dwhen determining regulatory  
reporting requirements.
If the investiga tor does not know whether or not the study  interventioncaused the 
event, then the event will be handled as “related to study  intervention ” for re porting 
purposes, as defined b y the spon
sor.  In addition, if the investigator determines that 
an SAE is assoc iated with study  procedures, the investigator m ust record this causal 
relationship in the source documents and CRF, and report such an assessment in the 
dedicated section of the CT SAE R eport Form and in accordance with the SAE 
reporting requirements.
Follow-up of AEs and SAEs
The investigator is ob ligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medica lly indicated or as requested by  [CONTACT_107104]/or causalit y of the AE or SAE as fully  as 
possible. This may include additional laboratory  test
s or investigations, 
histopathological examinations, or consultation with other hea lthcare providers.
If a participant dies during participation in the study  or during a recognized 
follow -up pe riod, the investigator wi ll provide [COMPANY_007] Safe tywith a cop y of any  
postmortem findings including histopathology .
New or updated information will berecorded in the originally  completed CRF.
The investigator will submit any  updated SAE data to the sponsor within 24 hours 
of recei pt of the information.

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page 7410.3.4. Reporting of SAEs
SAE Reporting to [COMPANY_007] Safety via an Electronic Data Collection Tool
The pri mary mechanism for reporting an SAE to [COMPANY_007] Safety will be the electronic 
data collection tool.
If the elect ronic s ystem is unavailable, then the site will use the paper S AE data 
collection tool (
see next section) in order to report the event within 24 hours.
The site will enter the SAE data into the elec tronic sy stem as soon as the data
become available.
After the study  is completed at a given site, the ele ctronic data col lection tool will 
be taken off -line to prevent the entry  of new data or changes to e
xisting data.
If a site receives a report of a new SAE from a study  participant or receives updated 
data on a previously  reported SAE after the electronic d
ata collection t ool has been 
taken off -line, then the site can report this information on a paper S AE f orm (see 
next section) or to Pfize rSafety  by [CONTACT_756].
SAE Reporting to [COMPANY_007] Safety via CT SAE Repor t Form
Facsimile transmission of the CT SAE Re port Form is the preferred method to 
transmit this information to [COMPANY_007] Safety .
In circumstances when the facsimile is not working , noti fication b y telephone is 
acceptable with a cop y of the CT SAE 
Report For msent by  [CONTACT_20022].
Initial notification via telephone does not replace the need for the investigator to 
complete and sig n the CT SAE Report Form pages w ithin the designated reporting 
time frames.

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page 7510.4. Appendix 4: Contraceptive Guidanc e
10.4.1. Male Participant Reproductive Inclusion Crite ria
No contraception methods are required for male participants in this study , as the calculated 
safety margin is ≥100- fold betwee n the estimated maternal exposure due to seminal transfer 
and the NOAEL for serious manifestations of developmental toxicity  in nonclinical studies.
10.4.2. Female Participant Reproductive Inclusion Criteria
A female participant is e l
igible to part icipate if she i s not pregnant or breastfeeding, and at 
least 1 of the following conditions applies:
Is not a WOCBP (see definitions below inSection 10.4.3);
OR
Is a WOCBP and us i
nga contracep tive method that is highly  effective (with a failure 
rate of <1% per y ear), as described below, during the intervention period and for at 
least [ADDRESS_118969] dose of study  intervention ,which corresponds to the time 
needed to elimin ateany reproductive safet y risk of the study  intervention(s) .If a 
highly effective method that is user dependent is chosen, a second effective method of 
contraception, as described below, must alsobe used.  The investigator should 
evaluate the effectiv eness of the co ntraceptive method in relationship to the first dose 
of study intervention.
The investigator is responsible for review of medical history , menstrual history , and recent 
sexual activity  to decrease the risk for inclusion of a woman with an ea rlyundetected 
pregnancy . 
10.4.3. Woman of Childbearing Potential
A woman is co nsidered fertile following menarche and until becoming postmenopausal 
unless permanentl y sterile (see below).
If fertility  is unclear (eg, amenorrhea in adolescents or athletes) and a 
menstrual cy clecannot 
be confirmed before the 
first dose of study  inter vention, additional evaluation should be 
considered.
Women in the following categories are notconsidered WOCBP:
1.Premenarchal .
2. P remenopausal female with 1 of the following:
Documente d hysterectomy ;
Documented bilateral salpi[INVESTIGATOR_1656] ;

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page 76Documented bilateral oophorectom y.
For individuals with permanent infertility  due to an alternate medical cause other than 
the above, (eg, mullerian agenesis, androgen insensitivity ), investigator discret i
on
should be a pplied to determining study  entry .
Note: Documentation fo r any of the above 
categories can come from the site 
personnel’s review of the participant’s medical records, medical examination, or 
medical history  interview.   The method of documentati on should be recorded in the 
participant’s medical record for the stu dy.
3.Postmenopausal female .
A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause. In addition, a
High FSH level in the postmenopausal range m
ust be used t o confirm a 
postmenopausal state in women under 60 years old and not using hormonal 
contraception or HRT. 
Female on HRT and whose menopausal status is in doubt will be required to 
use one of the nonestrogen hormonal highl y effective contrac e
ption methods 
if they  wish to continue their HRT during the study .
  Other wise, they  must 
discontinue HRT to allow confirmation of postmenopausal status before study  
enrollment.
10.4.4. Contracepti onMethods
Contraceptive use b y men or women should be consistent w i
thlocal avail ability /regulations 
regarding the use of contraceptive me thods for those participating in clinical trials.
1.Implantable progestogen -only hormone contraception associated with inhibition of 
ovulation
.
2.Intrauterine device .
3.Intrauterine hormone -releasing s ystem.
4.Bilateral tubal occlusion .
5.Vasectomized partner .
Vasec tomized partner is a highl y effective contraceptive method provided that the 
partner is the sole sexual partner of the woman of childbearing potential and the 
absence of sperm has been confirmed. Ifnot, an additional highly  effective 
method of contracept
ion should be used. The s permatogenesis cy cle is 
approximately  90days.

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page 776.Combined (estrogen- and progestogen -containing) hormonal contraception associated 
with inhibition of ovulation .
Oral;
Intrav aginal;
Transdermal ;
Injectable .
7.Progestogen -only hormone c ontraception associated with inhibition of ovulation .
Oral;
Injectable .
8.Sexual abstinence .
Sexual abstinence is considered a highl y effective method only  if defined as 
refraining from 
heterosexual intercourse during the entire period of risk associated 
with the study  intervention. The reliability  of sexual abstinence needs to be 
evaluated in relation to the duration of the stud y and the preferred and usual 
lifesty le of the participant.
I
naddition, 1of the following effective barrier methods must also be used when 
option 6 or 7 are chosen above:
Male or female condom with or without spermicide;
Cervical cap, diaphragm, or sponge with spermicide;
A combination of male condom with either ce rvical cap, diaphragm, or sponge with 
spermicide (double -barrier m ethods) .

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page 7810.5. Appendix 5: Genetics
Use/Analysis of DNA
Genetic variation may  impact a participant’s response to study  intervention, 
susceptibility  to, and severity  and progression of disease. Therefore, whe re local 
regulations and IRB s/ECsallow, a blood samp lewill be collected for DNA anal ysis.
The scope of the genetic research may  benarrow (eg, 1or more candidate genes ) or
broad (eg,the entire genome ),as appropriate to the scientific qu estion under 
investigation.
The samples may  be analy zed as part of a multistudy  assessment of genetic factors 
involved in the response to PF-06882961 or study  interventions of this class to 
understand treatments for the disease under s tudy or the disease them selves.
The results of genetic analy ses may  be reported in the C SRor in a separate study  
summary , or may  be used for internal decision making without being included in a 
study  report.
The sponsor will store the DNA samples in a secure storage space wit h adequate 
meas ures to protect confidentiality . 
The samples will b e retained as indicated:
Samples for banking will be stored indefinitel y or for an other period as per local 
requirements.  
Participant s may  withdraw their consent for the storage and/or us e of their Bank ed 
Biospecimens at any  time by  [CONTACT_7328] a request to t heinvestigator; in this case, an y 
remaining material will be destro yed.  Data already generated from the samples will 
beretained to protect the integrit y of existing analyses.   
Banked Biospecimens willbe labeled with a code.  The key  between the code a ndthe 
participant ’s personally  identify ing information (eg ,name, address) will be held at the 
study  site and will not be provided to the sample bank.

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page 7910.6. Appendix 6: Liver Safety: Suggested Actions and Follow -up Assessments 
Potential Cases of Drug- Induce d Liver Injury
Humans exposed to a drug who show no sign of liver injury  (as determined by  [CONTACT_20023]) are termed “tolerators,” while those who show transient liver injury , but adapt 
are termed “adaptors.”  In some 
participant s, transamina seelevations are a harbinger of a 
more serious potential outcome.  These participant s fail to adapt and therefore are 
"susceptible" to progressive and serious liver injury, commonl y referre d to as DILI.  
Participant s who experience a transaminase elevatio n above 3 ×ULN should be monitored 
more frequently  to determine if they  are an “adaptor” or are “susceptible.”
In the majority  of DILI cases, elevations in AST and/or ALT precede TBili elev
ations 
(>2×ULN) by [CONTACT_90051] s or weeks.  The incr ease in TBili typi[INVESTIGATOR_22774]/AL T is/are still elevated above 3 ×ULN (ie, AST/AL T and TBili values will be 
elevated within the same lab oratory sample).  In rare instances, by  [CONTACT_107105] e levations 
are d etected, AST/ALT values might have dec reased.  This occurrence is still regarded as a 
potential DILI.  Therefore, abnormal elevations in either AST OR ALT in addition to TBili 
that meet the criteria outlined below are considered potential DI L
I(assessed pe r Hy’s law 
criteria) cases and should alway s be consi dered important medical events, even before all 
other possible causes of liver injury  have been excluded.
The threshold of laboratory  abnormalities for a potential DILI case depends on the
participant ’s individual baseline values and underly ing condition s.  Participant s who present 
with the following laboratory  abnormalities should be evaluated further as pote ntial DILI 
(Hy’s law) cases to definitively  determine the etiology  of the abnormal laboratory  values:
Participant s with AST/ALT and TBili baseline v alues within the normal range who 
subsequently  present with AST OR AL T values >3 ×ULN AND a TBili value 
>2× ULN with no evidence of hemol ysis and an alkaline phosphatase value 
<2×ULN or notavailable.
For participant s with baseline AST 
OR ALT ORTBili values above the ULN, the 
following threshold values are used in the definition mentioned above, as needed, 
depending on which values are above the ULN at baseline:
Preexisting AST or ALT ba seline values a bove the normal range: AST or ALT 
values >2 times t he baseline values AND >3 ×ULN; or >8 ×ULN (whichever is 
smaller).
Preexisting values of TBili above the n ormal range: TBili level increased from 
baseline value b y an amount of at least 1 × U LN orif the value reaches 
>3×ULN (whichever is smaller).

PF-[ADDRESS_118970]/AL T and TBili separated b y more than a few weeks should be assessed 
individually  based on clinical judgment; an y case where uncertainty  remains as to whether it 
represents a potent ialHy’s law ca se should be reviewed with the sponsor.  
The participant should return to the investigator site and be evaluated as soon as possible, 
preferabl y within [ADDRESS_118971] and AL T and TBili for suspected cases of 
Hy’s law, additional laboratory  tests should include albumin, CK, direct and indirect 
bilirubin, GGT, PT/I NR, tota l
bile acids, and alkaline phosphatase.  Consideration should 
alsobe given to drawing a separate tube of clotted blood and an anticoagulated tube of blood 
for further testin g, as needed, for further contemporaneous anal yses at the time of the 
recognized i nitial abnormal ities to determine etiology .  A detailed history , including relevant 
information, such as review of ethanol, acetaminophen /paracetamol (either by  [CONTACT_20025] a 
coformulated product in prescription or over -the-
counter medications) , recreatio naldrug, 
suppl
ement (herbal) use and consumption, family  history , sexual history , travel history , 
history  of contact [CONTACT_4490] a jaundiced person, surger y, blood transfusion, history  of liver or 
allergic disease, and potential occupational exposure to chemical s,should be collected.  
Further testing for acute hepatitis A, B, C, D, and E infection and liver imaging (eg, biliary  
tract) and collection of serum sample s for acetaminophen /paracetamol drug and/or protein 
adduct levels may be warranted. 
All cases demo nstrated on repeat testing as meeting the laboratory  criteria of A ST/ALT and 
TBili elevation defined above should be considered potential DILI (Hy ’s law) cases if no 
other reason for the LFT abnormalities has yet been found.  
Such potential DILI (Hy’s law)
cases are to b e reported as SAEs, irrespective of availability of all the results of the 
investigations performed to determine etiology of the LFT a bnormalities.
A potential DILI (Hy ’s law) case becomes a confirmed case onl y after all results of 
reasonab l
einvestigatio ns have been received and have excluded an alternat ive etiology .

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page 8110.7. Appendix 7: ECG Findings of Potential Clinical Concern
ECG Findings T hat May Q ualify as A Es
Marked sinus bradycardia (rate <40 bpm) lasting minutes.
New PR interval prolongation >280 ms ec .
New prolongation of QTcF to >480 ms ec(absolute) or by ≥60msecfrom baseline .
New -onset atrial flutter or fibrillation, with controlled ventricular response rate: ie, 
rate<120 bpm .
New -
onset typeI second - degree (Wenckebach) AV block of >30 seconds ’durat ion.
Frequent PVCs, triplets , orshort intervals (<30 seconds) of consecutive ventricular 
complexes .
ECG Findings T hat May Q ualify as S AEs
QTcF prolongation >500 ms ec.
New ST- T changes suggestive of my ocardial ischemia .
New -onset l eft bundle branch block (QRS >120 ms ec).
New -onset right bundle b ranch block (QRS >120 ms ec).
Symptomatic bradycardia .
Asystole:
In awake, s ymptom -free participant s in sinus rhy thm, with documented periods 
of as ystole ≥3.0 seconds or an y escape rate <40 bpm, or with an escape rhy thm 
that is below the AV no de. 
In awake, s ymptom -free participant s with atrial fibrillation and brad ycardia 
with [ADDRESS_118972] 5 seconds or longer. 
Atrial f lutter or fibrillatio n,with rapid ventricular response rate: rapid = rate 
>120 bpm.
Sustained s upraventricular tachycardia (rate >120 bpm) (“sustained ”= short 
duration with relevant symptoms or lasting >1 minute) .
Ventricular r hythms >30 seconds’ duration, including idiovent ricular rh ythm (heart 
rate <40 bpm), accelerated idioventricular rh ythm (HR>40bpm to <100 bpm),and 

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page 82monomorphic/poly morphic ventricular tach ycardia (HR >100 bpm (such as
torsades de pointes) ).
Type IIsecond -degree (Mobitz II)AVblock.
Complete (third
-degree) heart block.
ECG Findings T hat Q ualify as S AEs
Change in pattern suggestive of new m yocardial infarction .
Sustained ventricular t achy arrhy thmias (>30 seconds ’duration) .
Second- or third -degree AV block requiring pacemaker pl acement .
Asystolic pauses requiring pacemaker placement.
Atrial flutter or fibrillation with rapid ventricular response requiring cardioversion .
Ventricular fibrillation/ flutter .
At the discretion of the investigator, an y arrh ythmia classified as an advers e 
experience .
The en umerated list of major events of potential clinical concern are recommended as “alerts ”or 
notifications from the core ECG lab oratory to the investigator and [COMPANY_007] study team ,and not to be 
considered as all inclusive of what to be re ported as AEs/SA Es.

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page 8310.8. Appendix 8: Child -Pugh Classification (CPC) of Liver Dysfunction 
Table 5.Scoring for Child Pugh Classification22
Cohort CPC Level of dysfunction Total Score
(tally based on assessment o f 
parameters in Table 6)
1 Not Applicable Without hepatic 
impairm entNotApplicable
2 A Mild 5-6
3 B Moderate 7-9
4 C Severe ≥10
Table 6. Derivation of Child Pugh Classification Score
Assessment Param et
ers Assigned score for observed findings
1 point 2 points 3 points
Encephalopath ygradea
(refer to Table 7below )0 1 or 2 3 or 4a
Ascites Absent Asymptomatic Requiring intervention
Serum total bilirubin, mg/dL <2 2 to 3 >3
Serum albumin, g/dL >3.5 2.8 to 3.5 <2.8
Prothrombin time, sec prolonged <4 4 to 6 >6
a.Partici pants with a prior history of Grade 3 or 4 encephalopathy who are currently receiving 
anintervention [for example: lactulose or lactitol, alone or in combi nation with rifaximin, and/or 
neomycin] to manage encephalopathy -related signs and symptoms should b escored for encephalopathy 
grading based on their presentation while on in tervention at the screening visit and can be included in 
Study C3421014 so long as they do nothave clinically a ctive Grade 3 or 4 encephalopathy.
Table 7. Determination of Encephalopathy Grade
Encephalopathy Grade Definition
0 Normal consciousness, personality, neurological exam
1 Restless, sleep disturbed, irrita ble/agitated, tremor, imp aired handwriting
[ADDRESS_118973]- disoriented, hyperactive reflexes, rigidity
4aUnrousable coma, no personality/behavior, dec erebrate
a.Subject s with clinically active Grade 3 or 4 encephalopathy are excluded.
CPC should be assessed at sc reening, only to determine the classification of a given 
participant .

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page 8410.9. Appendix 9: Prohibited Prior/Concomitant Medications
The foll owing medications are prohibited un til the follow -up visit ( ie, 28-[ADDRESS_118974] dose) , unless stated otherwise.  If a participant receives a prohibited medication, the 
investigator should contact [CONTACT_107106] t o determine if 
the participant shou ld be included in the stu dy.
Drug Classes and/or Drugs Timeframe of Restriction 
GLP -1R agonists 90 days prior to 
screening visit (S1)
DPP-4 inhibitors, pramlintide, repaglinide Screening visit (S1) to 
follow -up visit
Systemic glucocorticoids such a s prednisone, dexamethaso ne, triamcinolone, 
budesonide, bet amethasone.  Note: As an exception, steroid -containing 
inhalers, nasal sprays and topi[INVESTIGATOR_95471].  Screening visit (S1) to 
follow -up visit
Immunosuppressants such as cyclospor ine and tacrolimus. Screening visit (S1) to 
follow -up visit
Rosuvastatin.  Note: Other statins are permitted. Day 1 (day of dosing)
Sulfasalazine (sensitive BCRP substrate) Day 1 (day of dosing)
Use of ch ronic agents which are clinically significant OAT P inhibitors 
(eg,cyclosp orine, gemfibrozil, rifamp in).Day -1 to Follow -up visit
Use of chronic agents which are potent inducers of CYP3A (eg, rifampin, 
phenytoin, carbamazepi[INVESTIGATOR_050], phenobarbital).Screenin g visit (S1) to 
follow -up visit
Use of potent CYP3 A4 inhibitors (eg, ritonavir, indinavir, itra conazole, 
clarithromycin)Screening visit (S1) to 
follow -up visit
Use of moderate CYP3A4 inducers (eg , efavirenz, lopi[INVESTIGATOR_054], elagolix) Screening visit(S1) to 
follow -up visit
Use of moderate CYP3A4 inhibitors (eg, diltiazem, verapamil , erythromyc in, 
fluconazole)Screening visit (S1) to 
follow -up visit

PF-[ADDRESS_118975] aspartate aminotransferase
AUC 24 area under the plasma concentration -time profile from time zero to 
the time 24 hour s
AUC 24,free unbo und Area under the pla sma concentration -time profile from 
time zero to the time 24 hours 
AUC inf area under the plasma concentration -time profile from time zero
extrapolated to infinite time
AUC inf,u unbound area under the plasma concentratio n-time profi lefrom time 
zero ex trapolated to infinite time
AUC 0-inf The total AUC or AUC 0-is the area under the curve from time zero
extrapolated to infinite time
AUC last area under the plasma concentration -time profile from time zero to 
the time of t he last quan tifiable concentration
AUC last,u unbound area under the plasma concentration -time profile from time 
zero to the time of the last quantifiable concentration
AUC 0-last Area under the plasma concentration -time profile from time zero to 
the last measured con centration (AUC 0-last)
AUC 24, total Total Area under the plasma concentration -time profile from time 
zero to the time [ADDRESS_118976] cancer resistance protein 
BID twice a day
BMI body  mass index
BP blood pressur e
bpm beats per minute
BUN blood urea nitrogen
C Celsius
cAMP cyclic adenosine monophosphate
CFR Code of Federal Regu lations
CI confidence interval
CIOMS Council for International Organizations of Medical Sciences
CK creatine kinase
CL/F apparent clearance ofdrug from plasma

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page 86Term
CLu/F unbound apparent clearance from plasma
Clast last quantifiable concentration
Cmax maximum observed concentration
Cmax,free unbound maximum plasma contentration
Cmax,total total maxim um plasma concentr ation
Cmax,u unbound max imum plasma concentration
CO 2 carbon dioxide (bicarbonate)
COVID -[ADDRESS_118977] European Union Drug Regulating Authorities Clinical Tri als 
(European Clinical Trials Database)
FPG fasting plasma glucose
FSH follicle -stimulating hormone
Fu fraction unbound
GCP Good Clinical Practice
GGT gamma -glutamy l transf erase
GLP-[ADDRESS_118978]
HIV human imm unodefic iency  virus
HR Heart rat e
HRT hormone replacement therap y
IB Investigator’s Brochure
ICD informed consent document
ICH International Council for Harmonisation
IND Investigational New Drug Application
INR international n ormalized ratio
IP investigational produc t 
IPAL investigational product ad ministration log
IR Immediate release
IRB Institutio nal Review Board
IV intravenous
IVGTT intravenous glucose tolerance test
K2EDTA dipot assiu m ethy lenedia minetetraacetic ac id
Kel terminal phase rate constant calcul ated b y a linear regression of the 
log-linear concentration -time curve
LFT liver function test
MATE multidrug and toxin extrusion
MCH mean corpuscular hemoglobin
MCHC mean corpus cular hemoglobin concentration
MCV mean corpuscular volume
MEN2 multipleendocrine n eoplasia sy ndrome t ype 2
MRI magnetic resonance imaging
Msec millisecond (s)
MTC medullary  thyroid carcinoma
N/A not applicable
NOAEL noobserved adverse effect level
OAT organic an ion transporter
OCT 2 organic cation transport er 2
OATP organic anion -transporting pol ypeptide
PD pharmacod ynamic(s)
PE Physical exam
PI [INVESTIGATOR_19959](s)
PR pulse rate
PT prothrombin time

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page 88Term
PVC premature ve ntricular contra ction
QTc corrected QT interval
QTcF QTc corrected using Fridericia ’s formula
Qual qualitative
RBC red blood cell
SAE serious adverse event
SAP Statistical Analysis Plan
SARS -CoV -[ADDRESS_118979] identificatio n
SToD study  team on demand
S[LOCATION_003]R Suspected Unexpected Serious Adverse Reaction
t1/2 terminal phase half-life
T2DM type 2 diabetes mellitus
TBili total bilirubin
TEA E treatment -emergent adv erse event
THC tetrah ydrocannabinol
TIPS transjugular intrahepatic portosy stemic shunt
Tmax time to reach Cmax
UGT uridine 5’-diphosph ate-glucuronos yltransferase
ULN upper limit of normal
US [LOCATION_002]
Vz/F apparent vo lume of distribution
Vz,u/F unbound apparent volume of distribution
WBC white bl ood cell
WOCBP woman of childbearing potential

PF-[ADDRESS_118980] JJ, Knuhtsen S,et al. Glucagon -like peptides GL P-1 and GLP-2, 
predicted products of the glucagon gene, are secreted separate ly from pig small intestine 
but not pancreas. Endocrinology  1986;119(4):1467 - 75.
2. Krey mann B, Williams G, Ghatei MA, et al.Glucagon -like peptide-1 7-36: a 
physiological incretin in man. Lancet 1987;2(8571):1300 -4.
3. Nauck MA, Niedereichh olz U, Ettler R, et al. Glucagon -like peptide 1 inhibition of 
gastric empt ying out weighs its insulinotropic effects in healthy  human
s. Am J Phy siol 
1997;273(5):E981-8.
4. Flint A, Raben A, Astrup A, et al. Gluc agon -like peptide [ADDRESS_118981] 1998;101(3):515
-20.
5. Hu FB. Globalization of diabetes : the role of diet, lifesty le and gene s. Diabetes Care 
2011;34:1 249-57.
6. IDF D
iabetesAtlas; 8thEdition: Avaiable from: http://w ww.idf.org/diabetesatlas.
Accessed : 04 Feb 2019 .
7. Menke A, Casagrande S, Geiss L , et al. Prevalence of and Trends in Diabetes Among
Adults in the [LOCATION_002], 1988-2012. JAMA 2015;314:1021.
8. DeFronzo RA. Fr om 
thetriumv irate to the ominous octet: a new pa radigm for the 
treatment of t ype 2 diabetes mellitus. Diabetes 2009;58:773 -95.
9. Stratton I M, Adler AI, Haw N, et al. Association of glycaemia with macrovascular a nd 
microvas cular complications of ty pe 2 diabe tes ([LOCATION_006]PDS 35) : prospective observational 
study . BMJ 2000;321:405-12.
10. Drucker DL. The ascending GLP-1 road from clinica l safety  to reduction of 
cardiovascular complications. Diabet es2018;67:1710-9. 
11. VICTOZA [P ackage inse rt], Drugs@FDA. 2016 Apr., Availabl efrom : 
http://www .accessdata.fda.gov/drugsatfda_docs/ label/2016/022341s025lbl.pdf .
Accessed :
04 Feb 2019.
12. Ozempic [Package insert], Dru gs@FDA. 2017 Dec., Available from : 
https://www.accessd ata.fda.gov/dru gsatfda_doc s/label/20 17/209637lbl.pdf .Accessed :
19 Jul 2019.
13.
Trulicity  [Package Insert], Drugs@FDA, 2017 Jan ., Available from : 
https://www.accessdata.fda.gov/drug satfda_docs/label/201 7/125469s007
s008lbl.pdf .
Accessed : 19 Jul 2019 .

PF-06882961 
Protocol C3421 014
Final Proto col, 05October 2020
PFIZ ER CONFIDENT IAL
Page 9014. American Dia betes Assoc iation. Standards of m edical care in diabetes -2019. Diabetes 
Care. 2019 ;Jan;4 2(Suppl 1):S1- S193.
15. Nolin TD, Naud J , Leblond FA ,et al. Emerging evidence of the imp act of kidney  
disease on drug met abolism and transport. Clin Pharmacol Ther. 2008;83:898–903.
16. Yeung CK, Shen DD, Th ummel KE , et al . Effects of chronic kidney  disease and u remia 
on hepatic drug metabolism and transport. Kidney I nt. 2014;
85:522–8.
17. TanML, Yoshida K, Zhao P, et al. Effect of chronic kidney  disease on nonrenal 
elimination p
athway s: a sy stematic assessment of CYP1A2, CYP2C8, CYP2C9, 
CYP2C19, and OAT P. Clin Pharm acol Ther . 2018; May:103(5):854 - 67.
18.
Lorenz M, Lawson F, Owens D, et al. Differential e ffects of glucagon -like peptide -1
receptor agonists on heart rate. Cardiovasc Diab etol. 2017; 16:6.
19. Centers for Dise ase Control and Prevention. Interim Clinical Guidance for Mana gement 
of Pa tients with Confirmed Coronavirus Disease ( COVI D-19). Avai lable from: 
https: //www .cdc.g ov/coronavirus/2019 -ncov/hcp/clinical -guidance-management -
patients.html .Accessed : 21 Sep 2020.
20. Centers for Disease Control and Prevention. Ov erviewof Te sting for SARS -CoV -
2 
(COVID -19). Available from: https://ww w.cd c.gov/coronavirus/ 2019- ncov/hcp/testing -
overview.html .Accessed :
22 Se p 2020 .
21. American Diabetes Assoc iation. Sta ndards of medical care indiabetes -2019. Diabetes 
Care 2019;42(Suppl 1):S 1-S193.
22. Pugh RN, Murray -Lyon IM, Dawson J L, Pi[INVESTIGATOR_107070], Williams R . Transection of the 
oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60(8):646.
